1.本发明涉及一种隐丹参酮衍生物、其制备方法及应用。
背景技术:2.据世界卫生组织国际癌症研究机构(iarc)公布的《癌症统计报告2020》结果表明,乳腺癌每年新增患者达226万,已攀升成为全球发病率首位的肿瘤类型,并且乳腺癌在女性中的死亡率远高于其他癌症,严重威胁全球女性健康。其中,三阴性乳腺癌(tnbc)占所有乳腺癌患者的15%-20%,已成为临床治疗中最为棘手的一种乳腺癌亚型。因为tnbc中缺乏明确治疗靶点,雌激素受体(er)、孕激素受体(pr)、人表皮生长因子受体(her2)表达均为阴性,无特效药物。与其他乳腺癌亚型相比,tnbc具有侵袭性强、增殖性高、预后较差等的特点。目前,临床中tnbc治疗主要依赖传统化疗,但往往效果不佳且毒副作用较大,亟需开发出更为安全有效的新型抗tnbc药物。
3.隐丹参酮是中药丹参的主要脂溶性成分之一,与其他丹参酮类化合物相比,其具有典型的菲并二氢呋喃环母核结构、一个手性中心及多个sp3杂化碳,从而呈现出多种独特的药理活性。
技术实现要素:4.本发明所要解决的技术问题是为了克服现有技术中治疗三阴性乳腺癌的药物结构较为单一,从而本发明提供了一种隐丹参酮衍生物、其制备方法及应用。
5.本发明是通过以下技术方案解决上述技术问题的。
6.本发明提供了一种如式i所示的隐丹参酮衍生物、其立体异构体或其药学上可接受的盐在制备治疗三阴性乳腺癌药物中的应用:
[0007][0008]
其中,环a中的虚线
“‑‑‑‑‑”
为单键或双键;
[0009]
r1、r2共同形成=x1,其中x1选自ch2、o、s和nh;
[0010]
或r1、r2分别独立地为氢或羟基;
[0011]
r3为氢、苯氧基或被一个或多个r
1-1
取代的苯氧基,其中,r为氢、c
6-c
10
芳基、被一个或多个r
1-1
取代的c
6-c
10
芳基、c
1-3
烷基、被一个或多个r
1-2
取代的c
1-3
烷基、c
2-3
烯基、被一个或多个r
1-3
取代的c
2-3
烯基、5-9元杂环烷基或被一个或多个r
1-4
取代的5-9元杂环
烷基,所述5-9元杂环烷基中的杂原子个数为1、2或3个,每个杂原子独立地为n、o或s;
[0012]
每个r
1-1
独立地为cn、no2、c
1-4
烷基、c
1-4
卤代烷基、c
1-4
烷氧基、c
1-4
卤代烷氧基、卤素、5-6元杂环烷基或被一个或多个r
2-1
取代的5-6元杂环烷基;所述5-6元杂环烷基中的杂原子个数为1、2或3个,每个杂原子独立地为n、o或s;
[0013]-1
r为氢或c
1-3
烷基;
[0014]
每个r
2-1
独立地为叔丁氧羰基;
[0015]
每个r
1-2
独立地为-nr
2-2r2-3
、c
6-c
10
芳基或6-10元杂芳基,所述6-10元杂芳基中的杂原子个数为1、2或3个,每个杂原子独立地为n、o或s;
[0016]r2-2
、r
2-3
分别独立地为氢、叔丁氧羰基或
[0017]r1-3
为c
6-c
10
芳基;
[0018]r1-4
为叔丁氧羰基;
[0019]
环c中的为
[0020]
x2选自ch2、o、s和nh;
[0021]
x3选自ch2、o、s和nh;
[0022]
r4与r5分别独立地为氢、c
1-3
烷基-c(o)o-、c
1-3
烷氧基或羟基。
[0023]
在一些方案中,r中,所述“c
1-3
烷基或被一个或多个r
1-2
取代的c
1-3
烷基”中的“c
1-3
烷基”为甲基、乙基、丙基或异丙基,优选甲基或乙基。
[0024]
在一些方案中,r中,所述“c
2-3
烯基或被一个或多个r
1-3
取代的c
2-3
烯基”中的“c
2-3
烯基”为乙烯基、丙烯基或异丙烯基,优选乙烯基。
[0025]
在一些方案中,r中,所述“c
6-c
10
芳基或被一个或多个r
1-1
取代的c
6-c
10
芳基”中的“c
6-c
10
芳基”为苯基。
[0026]
在一些方案中,r中,所述“5-9元杂环烷基”或“被一个或多个r
1-4
取代的5-9元杂环烷基”中的“5-9元杂环烷基”为含n的5-9元杂环烷基,优选更优选
[0027]
在一些方案中,r中,所述被一个或多个r
1-4
取代的5-9元杂环烷基为
[0028]
在一些方案中,r
1-1
中,所述c
1-4
烷基或c
1-4
卤代烷基中的c
1-4
烷基部分为甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基,优选甲基、乙基或叔丁基。
[0029]
在一些方案中,r
1-1
中,所述c
1-4
烷氧基或c
1-4
卤代烷氧基中的c
1-4
烷氧基部分为甲氧基、乙氧基、丙氧基、异丙氧基、正丁氧基、异丁氧基或叔丁氧基,优选甲氧基。
[0030]
在一些方案中,r
1-1
中,所述卤素为f、cl、br或i,优选f、cl或br,更优选f或cl。
[0031]
在一些方案中,r
1-1
中,所述“5-6元杂环烷基”或“被一个或多个r
2-1
取代的5-6元杂
环烷基”中的“5-6元杂环烷基”为含n原子的6元杂环烷基,优选
[0032]
在一些方案中,r
1-1
中,所述c
1-4
卤代烷氧基或c
1-4
卤代烷氧基中的“卤代”为氟代、氯代、溴代或碘代,优选氟代。
[0033]
在一些方案中,-1
r中,所述c
1-3
烷基为甲基、乙基、丙基或异丙基,优选甲基。
[0034]
在一些方案中,r
1-2
中,所述c
6-c
10
芳基为苯基。
[0035]
在一些方案中,r
1-2
中,所述6-10元杂芳基为含n的6-10元杂芳基,优选
[0036]
在一些方案中,r
1-2
中,所述
“‑
nr
2-2r2-3”为-nhboc或优选-nhboc。
[0037]
在一些方案中,r
1-3
为苯基。
[0038]
在一些方案中,r4中,所述c
1-3
烷基-c(o)o-为甲酰氧基、乙酰氧基或丙酰氧基。
[0039]
在一些方案中,r4中,所述c
1-3
烷氧基为甲氧基、乙氧基、丙氧基或异丙氧基。
[0040]
在一些方案中,r5中,所述c
1-3
烷基-c(o)o-为甲酰氧基、乙酰氧基或丙酰氧基。
[0041]
在一些方案中,r5中,所述c
1-3
烷氧基为甲氧基、乙氧基、丙氧基或异丙氧基。
[0042]
在一些方案中,r为氢、c
6-c
10
芳基、c
1-3
烷基、被一个或多个r
1-2
取代的c
1-3
烷基、被一个或多个r
1-3
取代的c
2-3
烯基或被一个或多个r
1-4
取代的5-9元杂环烷基,所述5-9元杂环烷基中的杂原子个数为1个,杂原子为n。
[0043]
在一些方案中,每个r
1-1
独立地为cn、no2、c
1-4
烷基、c
1-4
卤代烷基、c
1-4
烷氧基、c
1-4
卤代烷氧基、卤素、或被一个r
2-1
取代的6元杂环烷基,所述6元杂环烷基为含2个n原子的6元杂环烷基。
[0044]
在一些方案中,每个r
1-1
独立地为cn、no2、c
1-4
卤代烷基、c
1-4
烷氧基、卤素或
[0045]
在一些方案中,每个r
1-1
独立地为cn、no2、甲基、乙基、叔丁基、甲氧基、三氟甲基、三氟甲氧基、f、cl、br、或优选cn、no2、甲氧基、三氟甲基、f、cl、
[0046]
在一些方案中,每个r
1-2
独立地为-nr
2-2r2-3
或c
6-c
10
芳基。
[0047]
在一些方案中,每个r
1-2
独立地为-nhboc、苯基或优选-nhboc、或苯基。
[0048]
在一些方案中,当r1、r2形成=x1时,x1为o。
[0049]
在一些方案中,当环c中的为时,x2为o。
[0050]
在一些方案中,当环c中的为时,x3为o。
[0051]
在一些方案中,当环c中的为时,r4与r5分别独立地选自氢和c
1-3
烷基-c(o)o-。
[0052]
在一些方案中,环c中的为
[0053]
在一些方案中,式i为
[0054]
在一些方案中,r3为为为优选为优选为
[0055][0056]
在一些方案中,如式i所示的隐丹参酮衍生物选自如下任一结构:
[0057][0058]
在一些方案中,如式i所示的隐丹参酮衍生物选自如下任一结构:
[0059]
[0060][0061]
[0062]
在一些方案中,如式i所示的隐丹参酮衍生物优选为如下任一结构:
[0063][0064]
本发明提供了一种如式i所示的隐丹参酮衍生物、其立体异构体或其药学上可接受的盐:
[0065][0066]
其中,
“‑‑‑‑‑”
、r1、r2、r3和的定义均如前所述;
[0067]
并且满足以下条件:
[0068]
所述如式i所示的隐丹参酮衍生物不为以下任一结构:所述如式i所示的隐丹参酮衍生物不为以下任一结构:
[0069]
在一些方案中,如式i所示的隐丹参酮衍生物选自如下任一结构:
[0070][0071]
[0072][0073]
本发明还提供了一种如式i所示的隐丹参酮衍生物的制备方法,其可以为方法1、2、3、4或5:
[0074]
方法1包括如下步骤:在溶剂中,将如式ii所示的化合物和r
3-h在氧化剂的存在下进行如下所示的共轭加成反应,得到如式i所示的隐丹参酮衍生物;其中,环a中的虚线
“”
为单键,r1、r2、r3和的定义如前所述,且r3不为氢;
[0075][0076]
方法2包括如下步骤:在溶剂中,将如式iii所示的化合物和酰化试剂在还原剂和无机碱的存在下进行如下所示的还原酰化反应,得到如式i所示的隐丹参酮衍生物;其中,环c中的为r4与r5分别独立地为c
1-3
烷基-c(o)o-;环a中的虚线
“‑‑‑‑‑”
、r1、r2、r3的定义如前所述;
[0077][0078]
方法3包括以下步骤:在溶剂中,将如式iv所示的化合物在无机碱存在下水解,同时d环二氢呋喃环进行开环反应,在无机酸存在下d环进行闭环反应,得到如式i所示隐丹参酮衍生物;其中,环c中的为r1、r2、x2、x3与r的定义如前所述,r3为氢原子;环a中的虚线
“‑‑‑‑‑”
为双键;
[0079][0080]
方法4包括以下步骤:在溶剂中,将如式v所示的化合物与氧化剂进行烯丙位氧化反应得到如式i所示的隐丹参酮衍生物;其中,r3为h;环a中的虚线
“‑‑‑‑‑”
为双键;r1、r2与的定义如前所述;r1、r2共同形成=x1,其中x1为o;或r1、r2中一个为氢,一个为羟基;
[0081][0082]
方法5包括以下步骤:在溶剂中,将如式vi所示的化合物在还原剂存在下进行还原反应,得到如式i所示隐丹参酮衍生物;其中,r3为h;环a中的虚线
“‑‑‑‑‑”
为单键;r1、r2与的定义如前所述;
[0083][0084]
在一些方案中,方法1中,所述溶剂选自本领域此类反应常规有机溶剂,优选甲苯或氯苯。
[0085]
在一些方案中,方法1中,所述氧化剂为氧气、叔丁基过氧化氢、二叔丁基过氧化物、2,2,6,6-四甲基哌啶氧化物(tempo)或二氧化锰,优选2,2,6,6-四甲基哌啶氧化物(tempo)。
[0086]
在一些方案中,方法1中,所述共轭加成反应的反应温度为0℃-130℃,优选100℃-130℃,特别优选120℃-130℃。
[0087]
在一些方案中,方法1中,所述氧化剂与所述如式ii所示的化合物的摩尔比为(1:1)-(100:1),优选(1:1)-(2:1);r
3-h与所述如式ii所示的化合物的摩尔比为(1:1)-(100:1),优选(1:1)-(4:1)。
[0088]
在一些方案中,方法2中,所述无机碱选自本领域此类反应常规无机碱,优选醋酸钠或醋酸钾。
[0089]
在一些方案中,方法2中,所述酰化试剂为酸酐或酰氯,优选醋酐、乙酰氯、丙酸酐或丙酰氯。
[0090]
在一些方案中,方法2中,所述还原剂为锌粉、氢化铝锂、硼氢化钠或氢气/钯,优选锌粉或硼氢化钠。
[0091]
在一些方案中,方法2中,所述还原酰化反应中的反应温度为0℃-50℃,优选25℃-50℃,特别优选40℃-50℃。
[0092]
在一些方案中,方法2中,所述酰化试剂与所述如式iii所示的化合物的摩尔比为(2:1)-(100:1),优选(4:1)-(20:1)。
[0093]
在一些方案中,方法2中,所述无机碱与所述如式iii所示的化合物的摩尔比为(1:
1)-(100:1),优选(1:1)-(2:1)。
[0094]
在一些方案中,方法2中,所述还原剂与所述如式iii所示的化合物的摩尔比为(2:1)-(100:1),优选(4:1)-(20:1)。
[0095]
在一些方案中,方法3中,所述溶剂选自本领域此类反应常规有机溶剂,优选甲醇和/或乙醇。
[0096]
在一些方案中,方法3中,所述无机碱选自本领域此类反应常规无机碱,优选氢氧化钠和/或氢氧化锂。
[0097]
在一些方案中,方法3中,所述无机酸选自本领域此类反应常规无机酸,优选硫酸或盐酸。
[0098]
在一些方案中,方法3中,所述开环反应与闭环反应的反应温度为0℃-70℃,优选25℃-70℃,特别优选25℃-56℃。
[0099]
在一些方案中,方法3中,所述无机碱与所述如式iv所示的化合物的摩尔比为(2:1)-(100:1),优选(4:1)-(20:1)。
[0100]
在一些方案中,方法3中,所述无机酸与所述如式iv所示的化合物的摩尔比为(1:1)-(100:1),优选(10:1)-(100:1)。
[0101]
在一些方案中,方法4中,所述溶剂选自本领域此类反应常规有机溶剂,优选二氧六环。
[0102]
在一些方案中,方法4中,所述氧化剂为氧气、叔丁基过氧化氢、二叔丁基过氧化物、2,2,6,6-四甲基哌啶氧化物(tempo)、二氧化锰、硝酸铈铵、醋酸二碘苯、过二硫化钾、二氧化硒和三氧化铬中的一种或多种,优选二氧化硒或二氧化硒和叔丁基过氧化氢的混合。
[0103]
在一些方案中,方法4中,所述烯丙位氧化反应的反应温度为0℃-100℃,优选25℃-100℃,特别优选50℃-100℃。
[0104]
在一些方案中,方法4中,所述氧化剂与所述如式v所示的化合物的摩尔比为(2:1)-(100:1),优选(4:1)-(20:1)。
[0105]
在一些方案中,方法5中,所述溶剂选自本领域此类反应的常规有机溶剂,优选四氢呋喃和/或二氯甲烷。
[0106]
在一些方案中,方法5中,所述还原剂为锌粉、氢化铝锂、硼氢化钠或氢气/钯,优选氢气/钯。
[0107]
在一些方案中,方法5中,所述还原反应的反应温度为0℃-50℃,优选25℃-50℃,特别优选25℃-35℃。
[0108]
在一些方案中,方法5中,所述还原剂与所述如式vi所示的化合物的摩尔比为(2:1)-(100:1),优选(4:1)-(20:1)。
[0109]
在不违背本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
[0110]
本发明所用试剂和原料均市售可得。
[0111]
本发明的积极进步效果在于:本发明提供了一种结构新颖的隐丹参酮衍生物、其制备方法及应用。本发明的隐丹参酮衍生物对三阴性乳腺癌细胞具有很好的抑制活性。
附图说明
[0112]
图1为化合物9-1抑制体内肿瘤的生长(n=5)
[0113]
图2为化合物13-1抑制体内肿瘤的生长(n=5)
[0114]
图3为化合物9-1、13-1抑制体内肿瘤的生长(n=5)
[0115]
图4为肿瘤切片的he染色及ki67免疫组化结果
[0116]
图5为给药后的小鼠体重变化曲线
[0117]
图6为主要脏器切片的he染色结果
具体实施方式
[0118]
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
[0119]
实施例1
[0120]
取隐丹参酮(100mg,0.337mmol)溶于3ml氯苯中,依次加入88%甲酸(29μl,0.675mmol),tempo(63mg,0.405mmol),120℃下搅拌反应24h,tlc监测反应结束后,80℃,真空度0.1mpa旋转蒸发仪减压浓缩得粗产物,冷却至室温,硅胶柱层析(石油醚:乙酸乙酯(pe:etoac)=2:1-0:1))得桔黄色固体化合物1-1(20mg,17%)。
[0121][0122]1h nmr(500mhz,cdcl3)δ8.09(s,1h),7.74(d,j=8.2hz,1h),7.68(dd,j=8.2,1.5hz,1h),6.66(t,j=3.4hz,1h),4.90(t,j=9.6hz,1h),4.38(ddd,j=9.4,6.0,1.5hz,1h),3.60(dqd,j=15.0,6.7,1.8hz,1h),2.26
–
2.15(m,1h),2.05
–
1.90(m,2h),1.56(ddd,j=12.7,4.1,1.9hz,1h),1.40(d,j=1.9hz,3h),1.34(dd,j=6.8,1.8hz,3h),1.27(d,j=2.9hz,3h).
13
c nmr(126mhz,cdcl3)δ183.08,174.63,170.18,160.25,152.82,136.38,133.45,128.69,127.27,125.43,118.74,81.62,67.21,34.89,34.62,31.85,31.51,31.13,24.85,18.75.hrms(esi):c
20h21o5+
[m+h]
+
m/z计算值:341.1384,实测值:341.1384.
[0123]
实施例2
[0124]
取隐丹参酮(100mg,0.337mmol)溶于3ml乙酸中,加入tempo(63mg,0.405mmol),120℃下搅拌反应24h,tlc监测反应结束后,80℃,真空度0.1mpa旋转蒸发仪减压浓缩得粗产物,冷却至室温,硅胶柱层析(pe:etoac=2:1-0:1)得桔黄色固体化合物2-1(89mg,75%)。
[0125]
[0126]1h nmr(500mhz,cdcl3)δ7.73(d,j=8.2hz,1h),7.66(dd,j=8.2,1.2hz,1h),6.45(dd,j=5.8,3.7hz,1h),4.90(td,j=9.5,3.2hz,1h),4.38(ddd,j=9.3,6.0,1.1hz,1h),3.60(dpd,j=10.0,6.8,3.4hz,1h),2.25
–
2.18(m,1h),2.01(d,j=3.7hz,3h),1.99
–
1.87(m,2h),1.58
–
1.52(m,1h),1.40(d,j=2.1hz,3h),1.35(dd,j=6.8,1.3hz,3h),1.27(d,j=2.9hz,3h).
13
c nmr(126mhz,cdcl3)δ183.23,174.96,170.27,169.94,152.82,137.29,133.30,129.03,127.19,125.17,118.66,81.60,67.18,34.94,34.64,32.12,31.57,31.18,24.52,21.05,18.80.hrms(esi):c
21h23o5+
[m+h]
+
m/z计算值:355.1540,实测值355.1541.
[0127]
实施例3
[0128]
制备方法同1-1,以丙酸(50μl,0.675mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物3-1(56mg,45%)及其非对映异构体3-2(61mg,49%)。
[0129][0130]
3-1:1h nmr(500mhz,cdcl3)δ7.72(d,j=8.2hz,1h),7.65(d,j=8.2hz,1h),6.47(t,j=3.7hz,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.3,6.0hz,1h),3.59(dp,j=9.6,6.7hz,1h),2.34
–
2.14(m,3h),2.03
–
1.85(m,2h),1.57
–
1.50(m,1h),1.39(s,3h),1.34(d,j=6.8hz,3h),1.26(s,3h),1.11(t,j=7.5hz,3h).
13
c nmr(126mhz,cdcl3)δ183.28,175.04,173.24,170.26,152.78,137.42,133.22,129.11,127.13,125.09,118.59,81.56,66.99,34.92,34.64,32.17,31.53,31.22,27.49,24.55,18.81,9.16.hrms(esi):c
22h25o5+
[m+h]
+
m/z计算值:369.1697,实测:369.1697.
[0131]
3-2:1h nmr(500mhz,cdcl3)δ7.72(d,j=8.2hz,1h),7.65(d,j=8.2hz,1h),6.46(t,j=3.6hz,1h),4.90(t,j=9.5hz,1h),4.37(dd,j=9.4,6.1hz,1h),3.60(dp,j=9.6,6.7hz,1h),2.34
–
2.14(m,3h),2.01
–
1.85(m,2h),1.57
–
1.51(m,1h),1.39(s,3h),1.35(d,j=6.8hz,3h),1.27(s,3h),1.13(t,j=7.5hz,3h).
13
c nmr(126mhz,cdcl3)δ183.25,175.08,173.27,170.30,152.82,137.43,133.28,129.05,127.15,125.12,118.63,81.58,66.95,34.94,34.64,32.15,31.62,31.15,27.45,24.57,18.75,9.15.hrms(esi):c
22h25o5+
[m+h]
+
m/z计算值:369.1697,实测值369.1697.
[0132]
实施例4
[0133]
制备方法同1-1,以苯甲酸(82mg,0.675mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物4-1(41mg,29%)及其非对映异构体4-2(45mg,32%)。
[0134][0135]
4-1:1h nmr(500mhz,cdcl3)δ7.95
–
7.91(m,2h),7.78(d,j=8.3hz,1h),7.70(d,j=8.2hz,1h),7.49
–
7.44(m,1h),7.37
–
7.30(m,2h),6.78(t,j=3.1hz,1h),4.87(t,j=
9.4hz,1h),4.37(dd,j=9.4,5.8hz,1h),3.56(dp,j=9.6,6.4hz,1h),2.41
–
2.31(m,1h),2.04
–
2.00(m,2h),1.62
–
1.55(m,1h),1.45(s,3h),1.33(d,j=6.9hz,3h),1.30(s,3h).
13
c nmr(126mhz,cdcl3)δ182.86,174.76,170.12,165.38,152.95,137.14,133.34,132.53,130.67,129.68(2c),129.06,128.10(2c),127.19,125.24,118.71,81.56,67.38,35.03,34.64,32.21,31.78,31.25,24.65,18.88.hrms(esi):c
26h25o5+
[m+h]
+
m/z计算值:417.1697,实测值417.1696.
[0136]
4-2:1h nmr(500mhz,cdcl3)δ7.97
–
7.91(m,2h),7.77(d,j=8.3hz,1h),7.69(d,j=8.3hz,1h),7.49
–
7.43(m,1h),7.33(t,j=7.7hz,2h),6.75(t,j=2.8hz,1h),4.89(t,j=9.6hz,1h),4.35(dd,j=9.4,6.2hz,1h),3.57(dp,j=9.7,6.7hz,1h),2.41
–
2.35(m,1h),2.04
–
1.99(m,2h),1.60
–
1.55(m,1h),1.44(s,3h),1.32
–
1.27(m,6h).
13
c nmr(126mhz,cdcl3)δ182.77,174.75,170.20,165.34,152.98,137.05,133.44,132.52,130.70,129.67(2c),128.94,128.10(2c),127.18,125.31,118.68,81.58,67.25,35.04,34.61,32.14,31.90,31.15,24.66,18.63.hrms(esi):c
26h25o5+
[m+h]
+
m/z计算值:417.1697,实测值:417.1699.
[0137]
实施例5
[0138]
制备方法同1-1,以肉桂酸(101mg,0.675mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物5-1(34mg,23%)及其非对映异构体5-2(38mg,25%)。
[0139][0140]
5-1:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.3hz,1h),7.70
–
7.63(m,2h),7.47
–
7.42(m,2h),7.34
–
7.28(m,3h),6.68
–
6.64(m,1h),6.34(d,j=16.0hz,1h),4.87(t,j=9.5hz,1h),4.36(dd,j=9.3,5.9hz,1h),3.57(dp,j=9.6,6.7hz,1h),2.35
–
2.29(m,1h),2.06
–
1.93(m,2h),1.60
–
1.54(m,1h),1.43(s,3h),1.33(d,j=6.9hz,3h),1.29(s,3h).
13
c nmr(126mhz,cdcl3)δ182.95,174.82,170.11,165.77,152.88,144.66,137.19,134.67,133.28,129.94,128.90,128.71(2c),127.99(2c),127.19,125.20,118.67,118.43,81.55,67.03,34.99,34.64,32.13,31.63,31.24,24.59,18.85.hrms(esi):c
28h27o5+
[m+h]
+
m/z计算值:443.1853,实测值:443.1853.
[0141]
5-2:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.2hz,1h),7.68(d,j=3.0hz,1h),7.66(d,j=4.8hz,1h),7.48
–
7.42(m,2h),7.34
–
7.29(m,3h),6.65(t,j=2.8hz,1h),6.35(d,j=16.0hz,1h),4.89(t,j=9.5hz,1h),4.36(dd,j=9.4,6.1hz,1h),3.58(dp,j=9.7,6.6hz,1h),2.36
–
2.26(m,1h),2.05
–
1.94(m,2h),1.61
–
1.53(m,1h),1.43(s,3h),1.32(d,j=6.8hz,3h),1.29(s,3h).
13
c nmr(126mhz,cdcl3)δ182.92,174.83,170.15,165.78,152.90,144.66,137.17,134.67,133.35,129.94,128.95,128.71(2c),127.99(2c),127.20,125.23,118.69,118.42,81.56,66.97,34.99,34.63,32.09,31.71,31.15,24.59,18.69.hrms(esi):c
28h27o5+
[m+h]
+
m/z计算值:443.1853,实测值:443.1853.
[0142]
实施例6
[0143]
取dmap(56mg,0.463mmol)溶于20ml吡啶中,依次加入丁二酸酐(906mg,0.292mmol),天然冰片(310mg,2.013mmol),于58℃下搅拌反应5天,tlc监测反应结束后,58℃,真空度0.1mpa旋转蒸发仪减压浓缩得粗产物,冷却至室温,硅胶柱层析(pe:etoac=5:1-0:1)得白色泡沫状化合物(380mg,75%)。将粗产物溶于8ml氯苯中,依次加入隐丹参酮(221mg,0.747mmol),tempo(140mg,0.896mmol),制备方法同1-1,得桔黄色固体化合物6-1(92mg,22%)及其非对映异构体6-2(88mg,21%)。
[0144][0145]
6-1:1h nmr(500mhz,cdcl3)δ7.73(d,j=8.2hz,1h),7.66(d,j=8.2hz,1h),6.47(t,j=3.9,3.1hz,1h),4.90(t,j=9.5hz,1h),4.86(ddd,j=9.9,3.5,2.1hz,1h),4.38(dd,j=9.4,5.9hz,1h),3.60(dp,j=9.6,6.7hz,1h),2.79
–
2.70(m,1h),2.70
–
2.50(m,3h),2.35
–
2.15(m,2h),2.01
–
1.86(m,3h),1.76
–
1.62(m,2h),1.57
–
1.51(m,1h),1.40(s,3h),1.35(d,j=6.8hz,3h),1.39
–
1.17(m,2h),1.26(s,3h),0.95(dd,j=13.7,3.5hz,1h),0.87(s,3h),0.85(s,3h),0.78(s,3h).
13
c nmr(126mhz,cdcl3)δ183.29,174.95,172.66,171.09,170.21,152.84,137.10,133.27,129.12,127.17,125.17,118.64,81.58,80.03,67.47,48.72,47.76,44.84,36.59,34.92,34.64,32.13,31.52,31.19,29.60,29.19,27.94,27.09,24.54,19.66,18.84,18.79,13.44.hrms(esi):c
33h41o7+
[m+h]
+
m/z计算值:549.2847,实测值:549.2845.
[0146]
6-2:1h nmr(500mhz,cdcl3)δ7.72(d,j=8.3hz,1h),7.65(d,j=8.2hz,1h),6.44(t,j=3.5hz,1h),4.89(t,j=9.5hz,1h),4.83(ddd,j=9.9,3.5,2.2hz,1h),4.37(dd,j=9.3,6.1hz,1h),3.59(dp,j=9.5,6.7hz,1h),2.78
–
2.67(m,1h),2.66
–
2.50(m,3h),2.32
–
2.15(m,2h),2.00
–
1.85(m,3h),1.74
–
1.60(m,2h),1.56
–
1.50(m,1h),1.38(d,j=2.6hz,3h),1.34(d,j=6.8hz,3h),1.26(s,3h),1.32
–
1.12(m,2h),0.89(dd,j=13.9,3.6hz,1h),0.86(s,3h),0.84(s,3h),0.79(s,3h).
13
c nmr(126mhz,cdcl3)δ183.31,174.99,172.67,171.09,170.27,152.86,137.11,133.33,129.03,127.15,125.20,118.64,81.59,80.03,67.45,48.71,47.73,44.82,36.62,34.91,34.61,32.10,31.58,31.10,29.58,29.13,27.95,27.04,24.56,19.66,18.78,18.70,13.42.hrms(esi):c
33h41o7+
[m+h]
+
m/z计算值:549.2847,实测值:549.2845.
[0147]
实施例7
[0148]
取隐丹参酮(500mg,1.687mmol)溶于17ml氯苯中,依次加入丙酸(252μl,3.374mmol),tempo(316mg,2.024mmol),120℃下搅拌反应24h,tlc监测反应结束后,80℃,真空度0.1mpa旋转蒸发仪减压浓缩得粗产物,冷却至室温,硅胶柱层析(pe:etoac=3:1-1:1)得到一对非对映异构体的粗产物a。将粗产物a(513mg,1.392mmol)溶于13ml甲醇中,0℃下加入氢氧化钠(223mg,5.568mmol),65℃下搅拌反应,tlc监测反应结束后,冷却,依次加入浓盐酸(6ml)及水(12ml),中和多余的氢氧化钠,减压浓缩,乙酸乙酯(3
×
50ml)萃取,合并有机相,无水na2so4干燥,过滤,40℃,真空度0.1mpa旋转蒸发仪减压浓缩得粗产物b。取粗
产物b(449mg,1.359mmol)溶于13ml无水乙醇中,0℃下缓慢分批滴入浓硫酸(8ml),温度降至室温后,继续反应45min,tlc确认反应结束后,0℃下滴入饱和nahco3溶液(20ml),搅拌10min至没有气泡产生,减压浓缩,乙酸乙酯(3
×
50ml)萃取,合并有机层后依次水洗,饱和食盐水洗,无水naso4干燥,浓缩,硅胶柱层析(pe:etoac=8:1-2:1)得桔红色固体化合物7-1(215mg,43%)。(粗产物a的结构为粗产物b的结构为)
[0149]
7-1:1h nmr(500mhz,cdcl3)δ7.86(dt,j=10.3,1.8hz,1h),7.52(d,j=7.9hz,1h),7.47(d,j=7.9hz,1h),6.30(dt,j=10.2,4.6hz,1h),4.88(t,j=9.5hz,1h),4.35(dd,j=9.3,6.0hz,1h),3.59(dp,j=9.6,6.5hz,1h),2.26(dd,j=4.6,1.9hz,2h),1.34(d,j=6.8hz,3h),1.27(s,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ184.90,175.71,170.72,150.66,136.58,134.01,129.36,126.14,124.59,124.33,124.02,118.51,81.47,37.71,34.61,34.33,28.36,28.32,18.77.hrms(esi):c
19h19o3+
[m+h]
+
m/z计算值:295.1329,实测值295.1329.
[0150]
实施例8
[0151]
取7-1(75mg,0.255mmol)溶于3ml的1,4-二氧六环中,0℃下依次加入二氧化硒(84mg,0.765mmol),叔丁基过氧化氢(93μl,0.510mmol),55℃下加热反应,tlc监测反应结束后,50℃,真空度0.1mpa旋转蒸发仪减压浓缩得粗产物,冷却至室温,硅胶柱层析(dcm:meoh=100:1-20:1)得桔红色固体化合物8-1(24mg,30%)。
[0152][0153]
8-1:1h nmr(500mhz,cdcl3)δ9.01(d,j=10.5hz,1h),7.89(dd,j=10.2,4.6hz,1h),7.60(d,j=7.9hz,1h),7.52(dd,j=8.0,1.6hz,1h),6.37(ddd,j=10.6,6.6,4.3hz,1h),4.89(t,j=9.5hz,1h),4.36(dd,j=9.3,6.1hz,1h),4.10
–
4.05(m,1h),3.58(ddq,j=15.8,9.3,6.7hz,1h),1.38
–
1.33(m,6h),1.26(d,j=7.3hz,3h).
13
c nmr(126mhz,cdcl3)δ184.56,175.42,170.52,149.56,135.76,135.15,130.65,126.46,125.14,124.73,124.50,118.74,81.56,72.33,40.11,34.62,26.33,21.94,18.71.hrms(esi):c
19h19o4+
[m+h]
+
m/z计算值:311.1278,实测值:311.1278.
[0154]
实施例9
nmr(126mhz,cdcl3)δ184.05,175.42,170.75,151.11,142.12,132.88,127.83,126.57,123.00,118.46,81.50,73.87,39.97,34.57,29.27,26.23,25.94,25.26,18.82.hrms(esi):c
19h21o4+
[m+h]
+
m/z计算值:313.1434,实测值:313.1434.
[0164]
实施例11
[0165]
取隐丹参酮(100mg,0.337mmol)溶于3ml的醋酐中,依次加入锌粉(221mg,3.370mmol),醋酸钠(28mg,0.337mmol),50℃下搅拌反应1h左右,tlc确认反应完全后,过滤除去锌粉,收集滤液,减压浓缩,乙酸乙酯(3
×
10ml)萃取,合并有机相,无水硫酸钠干燥,过滤后减压浓缩,硅胶柱层析(pe:etoac=5:1-1:1)得白色固体化合物11-1(96mg,74%)。
[0166][0167]
11-1:1h nmr(500mhz,cdcl3)δ7.74(d,j=8.8hz,1h),7.42(d,j=8.9hz,1h),4.86(t,j=8.9hz,1h),4.30(dd,j=8.6,6.4hz,1h),3.75(dp,j=9.0,6.5hz,1h),3.16(s,2h),2.37(s,3h),2.34(s,3h),1.83
–
1.75(m,2h),1.69
–
1.64(m,2h),1.33
–
1.29(m,9h).
13
c nmr(126mhz,cdcl3)δ169.51,168.04,154.70,144.88,137.85,132.17,130.59,127.10,125.43,119.72,118.06(2c),79.42,38.25,36.93,34.82,31.77,31.72,29.60,21.04,20.48,20.07,18.88.hrms(esi):c
23h27o5+
[m+h]
+
m/z计算值:383.1853,实测值:383.1851.
[0168]
实施例12
[0169]
取7-1(32mg,0.109mmol)溶于2ml的醋酐中,依次加入锌粉(71mg,1.088mmol),醋酸钠(9mg,0.109mmol),50℃下搅拌反应1h左右,tlc确认反应完全后,过滤除去锌粉,收集滤液,减压浓缩,乙酸乙酯(3
×
10ml)萃取,合并有机相,无水硫酸钠干燥,过滤后减压浓缩,硅胶柱层析(pe:etoac=5:1-1:1)得白色固体化合物12-1(35mg,84%)。
[0170][0171]
12-1:1h nmr(500mhz,cdcl3)δ7.82(d,j=8.7hz,1h),7.46(d,j=8.7hz,1h),7.40(dt,j=10.2,1.8hz,1h),6.05(dt,j=9.9,4.8hz,1h),4.87(t,j=8.9hz,1h),4.32(dd,j=8.6,6.3hz,1h),3.76(dp,j=9.1,6.8hz,1h),2.36(s,3h),2.35(s,3h),2.26
–
2.19(m,2h),1.32(d,j=6.8hz,3h),1.30(s,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ168.94,168.12,154.68,144.55,138.12,131.87,127.26,126.49,125.36,124.29,122.70,121.58,118.77,117.87,79.51,37.18,36.90,34.44,27.75(2c),20.78,20.48,18.96.hrms(esi):c
23h25o5+
[m+h]
+
m/z计算值:381.1697,实测值:381.1696.
[0172]
实施例13
[0173]
取12-1(103mg,0.271mmol)溶于3ml干燥1,4-二氧六环中,氩气置换三次,加入二氧化硒(60mg,0.541mmol),在氩气氛围中100℃下回流反应30min,tlc监测反应结束后,过滤,浓缩,乙酸乙酯(3
×
10ml)萃取,合并有机相,无水硫酸钠干燥,过滤后浓缩,硅胶柱层析(二氯甲烷:甲醇(dcm:meoh)=100:1-20:1))得白色固体化合物13-1(50mg,47%)及9-1。
[0174][0175]
13-1:1h nmr(500mhz,cdcl3)δ8.71(d,j=10.5hz,1h),8.03(d,j=8.8hz,1h),7.52(d,j=8.8hz,1h),6.23(d,j=10.5hz,1h),4.90(t,j=8.9hz,1h),4.34(dd,j=8.7,6.4hz,1h),3.79(dp,j=9.2,6.8hz,1h),2.41(s,3h),2.36(s,3h),1.50(s,3h),1.49(s,3h),1.33(d,j=6.9hz,3h).
13
c nmr(126mhz,cdcl3)δ203.61,168.56,167.82,155.19,150.14,140.97,139.46,131.74,124.74,124.65,123.80,123.55,123.02,119.47,118.45,79.75,48.57,36.90,27.70,27.47,20.80,20.45,18.81.hrms(esi):c
23h23o6+
[m+h]
+
m/z计算值:395.1489,实测值:395.1489.
[0176]
实施例14
[0177]
取13-1(119mg,0.302mmol)、10%钯碳(19mg,0.181mmol)溶于10ml干燥四氢呋喃中,氢气置换三次,在氢气氛围中室温(15-25℃)搅拌反应,tlc监测反应结束后,过滤回收钯碳,25℃,真空度0.1mpa旋转蒸发仪减压浓缩得粗产物,冷却至室温,硅胶柱层析(dcm:meoh=100:1-20:1)得桔红色固体化合物14-1(11mg,9%)及14-2(75mg,62%)。
[0178][0179]
14-1:1h nmr(500mhz,cdcl3)δ7.87(d,j=8.7hz,1h),7.39(d,j=8.9hz,1h),4.89(t,j=8.9hz,1h),4.33(dd,j=8.7,6.4hz,1h),3.77(dp,j=9.1,6.7hz,1h),2.71(t,j=6.9hz,2h),2.36(s,3h),2.35(s,3h),1.68
–
1.59(m,2h),1.47(s,6h),1.33(d,j=6.8hz,3h).
13
c nmr(126mhz,cdcl3)δ214.48,169.11,167.98,154.87,143.99,138.46,131.84,129.19,126.45,124.34,121.47,118.92,118.27,79.58,48.14,36.95,36.93,27.64,27.48,27.40,20.89,20.45,18.85.hrms(esi):c
23h25o6+
[m+h]
+
m/z计算值:397.1646,实测值:397.1647.
[0180][0181]
14-2:1h nmr(500mhz,cdcl3)δ7.78(d,j=8.9hz,1h),7.40(d,j=8.9hz,1h),4.86(t,j=8.9hz,1h),4.30(dd,j=8.6,6.4hz,1h),3.77
–
3.71(m,2h),3.30(d,j=120.4hz,1h),2.36(s,3h),2.33(s,3h),2.02
–
1.93(m,2h),1.93
–
1.85(m,2h),1.34(d,j=2.5hz,3h),1.31(s,3h),1.30(s,3h).
13
c nmr(126mhz,cdcl3)δ169.53,168.00,154.69,143.55,138.05,132.21,129.09,126.59,125.34,120.44,118.47,118.17,79.46,74.57,39.99,36.94,27.08(2c),24.64,21.02,20.46,18.87,18.80.hrms(esi):c
23h27o6+
[m+h]
+
m/z计算值:399.1802,实测值:399.1803.
[0182]
实施例15
[0183]
隐丹参酮衍生物15-1及15-2的制备:
[0184]
取隐丹参酮(100mg,0.337mmol)溶于3ml氯苯中,依次加入苯酚(54mg,0.574mmol),tempo(105mg,0.675mmol),120℃下搅拌反应24h,tlc监测反应结束后,80℃,真空度0.1mpa旋转蒸发仪减压浓缩得粗产物,冷却至室温,硅胶柱层析(pe:etoac=3:1-1:1)得桔黄色固体化合物15-1(30mg,23%)及其非对映异构体15-2(33mg,25%)。
[0185][0186]
15-1:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.3hz,1h),7.68(d,j=8.2hz,1h),7.32
–
7.28(m,2h),7.15
–
7.12(m,2h),6.96(tt,j=7.3,1.1hz,1h),6.57(t,j=3.2hz,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.4,5.9hz,1h),3.65
–
3.53(m,1h),2.22(ddt,j=14.6,4.4,2.9hz,1h),2.11(td,j=13.7,2.9hz,1h),1.82(tt,j=14.2,3.1hz,1h),1.48
–
1.45(m,1h),1.45(s,3h),1.35(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.28,175.03,170.37,157.22,152.68,138.22,133.31,129.47(2c),128.92,127.21,125.10,121.04,118.45,116.83(2c),81.53,67.74,35.05,34.62,31.56,31.48,31.40,22.56,18.80.hrms(esi):c
25h25o4+
[m+h]
+
m/z计算值:389.1747,实测值:389.1747.
[0187]
15-2:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.3hz,1h),7.68(d,j=8.3hz,1h),7.32
–
7.27(m,2h),7.16
–
7.11(m,2h),6.95(tt,j=7.3,1.1hz,1h),6.59(t,j=3.2hz,1h),4.89(t,j=9.5hz,1h),4.38(dd,j=9.4,5.8hz,1h),3.64
–
3.55(m,1h),2.26
–
2.16(m,1h),2.15
–
2.04(m,1h),1.84(tt,j=14.3,3.2hz,1h),1.49
–
1.45(m,1h),1.45(s,3h),1.31(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.31,175.03,170.38,157.25,152.69,138.26,133.33,129.46(2c),128.88,127.22,125.11,121.02,118.57,116.74
(2c),81.53,67.70,35.05,34.58,31.61,31.50,31.29,22.55,18.85.hrms(esi):c
25h25o4+
[m+h]
+
m/z计算值:389.1747,实测值389.1747.
[0188]
实施例16
[0189]
制备方法同15-1,以4-硝基苯酚(80mg,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物16-1(47mg,32%)及其非对映异构体16-2(43mg,29%)。
[0190][0191]
16-1:1h nmr(500mhz,cdcl3)δ8.22
–
8.17(m,2h),7.80(d,j=8.3hz,1h),7.72(d,j=8.2hz,1h),7.12
–
7.07(m,2h),6.60(t,j=3.2hz,1h),4.89(t,j=9.5hz,1h),4.38(dd,j=9.4,5.9hz,1h),3.62
–
3.52(m,1h),2.24
–
2.15(m,1h),2.07
–
1.90(m,2h),1.55
–
1.50(m,1h),1.45(s,3h),1.33(d,j=6.8hz,3h),1.29(s,3h).
13
c nmr(126mhz,cdcl3)δ183.24,174.58,170.37,162.98,152.53,141.30,136.58,133.63,128.64,127.41,126.00(2c),125.64,118.67,115.79(2c),81.69,68.79,53.46,34.98,34.61,31.49,31.16,22.93,18.78.hrms(esi):c
25h24
no
6+
[m+h]
+
m/z计算值:434.1598,实测值:434.1597.
[0192]
16-2:1h nmr(500mhz,cdcl3)δ8.23
–
8.18(m,2h),7.80(d,j=8.2hz,1h),7.72(d,j=8.2hz,1h),7.12
–
7.08(m,2h),6.61(t,j=2.9hz,1h),4.91(t,j=9.5hz,1h),4.38(dd,j=9.4,6.0hz,1h),3.60(dp,j=9.8,6.8hz,1h),2.24
–
2.18(m,1h),2.08
–
1.90(m,2h),1.56
–
1.51(m,1h),1.45(s,3h),1.32(d,j=6.8hz,3h),1.30(s,3h).
13
c nmr(126mhz,cdcl3)δ183.28,174.65,170.31,162.99,152.53,141.31,136.62,133.64,128.61,127.43,126.01(2c),125.63,118.74,115.77(2c),81.67,68.78,34.98,34.60,31.54,31.48,31.10,22.94,18.75.hrms(esi):c
25h24
no
6+
[m+h]
+
m/z计算值:434.1598,实测值:434.1599.
[0193]
实施例17
[0194]
制备方法同15-1,以4-氰基苯酚(80mg,0.674mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物17-1(40mg,29%)及其非对映异构体17-2(38mg,27%)。
[0195][0196]
17-1:1h nmr(500mhz,cdcl3)δ7.79(d,j=8.3hz,1h),7.71(d,j=8.2hz,1h),7.61
–
7.57(m,2h),7.12
–
7.08(m,2h),6.57(t,j=3.1hz,1h),4.89(t,j=9.5hz,1h),4.38(dd,j=9.4,5.9hz,1h),3.58(dp,j=9.6,6.7hz,1h),2.23
–
2.15(m,1h),2.07
–
1.99(m,1h),1.96
–
1.87(m,1h),1.53
–
1.47(m,1h),1.45(s,3h),1.34(d,j=6.8hz,3h),1.29(s,3h).
13
c nmr(126mhz,cdcl3)δ183.24,174.67,170.32,161.06,152.54,136.84,134.04(2c),133.54,128.69,127.38,125.52,119.46,118.64,116.66(2c),103.71,81.64,68.26,
34.96,34.61,31.48,31.46,31.19,22.79,18.78.hrms(esi):c
26h24
no
4+
[m+h]
+
m/z计算值:414.1700,实测值:414.1697.
[0197]
17-2:1h nmr(500mhz,cdcl3)δ7.79(d,j=8.2hz,1h),7.71(d,j=8.2hz,1h),7.63
–
7.55(m,2h),7.13
–
7.08(m,2h),6.58(t,j=3.2hz,1h),4.90(t,j=9.5hz,1h),4.38(dd,j=9.4,6.0hz,1h),3.59(dp,j=9.7,6.7hz,1h),2.23
–
2.14(m,1h),2.03(td,j=13.4,2.5hz,1h),1.92(tt,j=14.2,2.9hz,1h),1.55
–
1.48(m,1h),1.44(s,3h),1.31(d,j=6.8hz,3h),1.29(s,3h).
13
c nmr(126mhz,cdcl3)δ183.27,174.71,170.33,161.10,152.55,136.87,134.03(2c),133.99,133.58,128.63,127.39,125.53,119.46,118.71,116.63(2c),103.68,81.64,68.25,34.96,34.58,31.53,31.47,31.11,22.80,18.74.hrms(esi):c
26h24
no
4+
[m+h]
+
m/z计算值:414.1700,实测值:414.1702.
[0198]
实施例18
[0199]
制备方法同15-1,以对羟基苯甲醛(70mg,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物18-1(43mg,31%)及其非对映异构体18-2(37mg,26%)。
[0200][0201]
18-1:1h nmr(500mhz,cdcl3)δ9.86(s,1h),7.85
–
7.81(m,2h),7.77(d,j=8.3hz,1h),7.69(d,j=8.2hz,1h),7.17
–
7.13(m,2h),6.62(t,j=3.1hz,1h),4.87(t,j=9.5hz,1h),4.35(dd,j=9.4,5.9hz,1h),3.60
–
3.51(m,1h),2.26
–
2.18(m,1h),2.09
–
2.00(m,1h),1.91(tt,j=14.2,3.1hz,1h),1.52
–
1.47(m,1h),1.44(s,3h),1.32(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ190.94,183.20,174.67,170.31,162.88,152.56,137.01,133.53,132.10(2c),129.86,128.71,127.34,125.48,118.61,116.24(2c),81.62,68.21,34.98,34.60,31.52,31.49,31.23,22.88,18.79.hrms(esi):c
26h25o5+
[m+h]
+
m/z计算值:417.1697,实测值:417.1696.
[0202]
18-2:1h nmr(500mhz,cdcl3)δ9.88(s,1h),7.86
–
7.82(m,2h),7.79(d,j=8.2hz,1h),7.71(d,j=8.2hz,1h),7.18
–
7.14(m,2h),6.64(t,j=3.2hz,1h),4.90(t,j=9.5hz,1h),4.38(dd,j=9.4,6.0hz,1h),3.59(dp,j=9.6,6.7hz,1h),2.26
–
2.20(m,1h),2.09
–
2.01(m,1h),1.94(tt,j=14.2,3.0hz,1h),1.54
–
1.47(m,1h),1.45(s,3h),1.31(d,j=6.8hz,3h),1.30(s,3h).
13
c nmr(126mhz,cdcl3)δ190.94,183.24,174.74,170.32,162.90,152.58,137.07,133.55,132.11(2c),129.89,128.67,127.36,125.48,118.69,116.21(2c),81.62,68.19,34.99,34.59,31.57,31.50,31.16,22.89,18.77.hrms(esi):c
26h25o5+
[m+h]
+
m/z计算值:417.1697,实测值:417.1695.
[0203]
实施例19
[0204]
制备方法同15-1,以对乙酰基苯酚(78mg,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物19-1(38mg,26%)及其非对映异构体19-2(40mg,
28%)。
[0205][0206]
19-1:1h nmr(500mhz,cdcl3)δ7.95
–
7.92(m,2h),7.77(d,j=8.3hz,1h),7.69(d,j=8.3hz,1h),7.11
–
7.07(m,2h),6.61(t,j=3.2hz,1h),4.88(t,j=9.5hz,1h),4.36(dd,j=9.4,5.9hz,1h),3.56(dp,j=9.5,6.6hz,1h),2.55(s,3h),2.25
–
2.16(m,1h),2.09
–
2.01(m,1h),1.90(tt,j=14.2,3.1hz,1h),1.51
–
1.46(m,1h),1.44(s,3h),1.33(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ196.96,183.21,174.73,170.31,161.68,152.56,137.24,133.47,130.68(2c),130.27,128.76,127.32,125.39,118.58,115.71(2c),81.60,68.00,34.99,34.61,31.52,31.49,31.26,26.37,22.84,18.79.hrms(esi):c
27h27o5+
[m+h]
+
m/z计算值:431.1853,实测值:431.1853.
[0207]
19-2:1h nmr(500mhz,cdcl3)δ7.95
–
7.90(m,2h),7.77(d,j=8.2hz,1h),7.69(d,j=8.2hz,1h),7.10
–
7.07(m,2h),6.61(t,j=3.1hz,1h),4.88(t,j=9.5hz,1h),4.36(dd,j=9.4,6.0hz,1h),3.62
–
3.52(m,1h),2.54(s,3h),2.24
–
2.18(m,1h),2.09
–
2.00(m,1h),1.91(tt,j=14.2,3.1hz,1h),1.52
–
1.45(m,1h),1.43(s,3h),1.29(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ196.92,183.25,174.78,170.31,161.72,152.58,137.26,133.51,130.67(2c),130.25,128.70,127.32,125.40,118.65,115.67(2c),81.59,68.00,34.98,34.57,31.57,31.50,31.16,26.37,22.84,18.77.hrms(esi):c
27h27o5+
[m+h]
+
m/z计算值:431.1853,实测值:431.1854.
[0208]
实施例20
[0209]
制备方法同15-1,以3-氯苯酚(57μl,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物20-1(37mg,26%)及其非对映异构体20-2(37mg,26%)。
[0210][0211]
20-1:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.3hz,1h),7.68(d,j=8.2hz,1h),7.20(t,j=8.1hz,1h),7.08(t,j=2.2hz,1h),7.00(dd,j=8.3,2.4hz,1h),6.92(dd,j=7.9,1.9hz,1h),6.50(t,j=3.3hz,1h),4.88(t,j=9.5hz,1h),4.36(dd,j=9.4,5.9hz,1h),3.57(dp,j=9.5,6.7hz,1h),2.23
–
2.17(m,1h),2.08
–
2.01(m,1h),1.84(tt,j=14.3,3.1hz,1h),1.50
–
1.45(m,1h),1.44(s,3h),1.33(d,j=6.8hz,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ183.18,174.78,170.47,158.11,152.64,137.57,134.76,133.46,130.27,128.72,127.25,125.33,121.09,118.54,116.94,114.85,81.63,68.12,35.01,
34.59,31.55,31.44,31.29,22.55,18.79.hrms(esi):c
25h24
clo
4+
[m+h]
+
m/z计算值:423.1358,实测值:423.1359.
[0212]
20-2:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.68(d,j=8.2hz,1h),7.20(t,j=8.1hz,1h),7.08(t,j=2.2hz,1h),7.00(dd,j=8.2,2.2hz,1h),6.92(dd,j=7.9,1.0hz,1h),6.52(t,j=3.1hz,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.4,5.9hz,1h),3.59(dp,j=9.5,6.7hz,1h),2.23
–
2.17(m,1h),2.04(td,j=13.7,2.9hz,1h),1.85(tt,j=14.3,3.1hz,1h),1.50
–
1.44(m,1h),1.43(s,3h),1.31(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.22,174.87,170.41,158.14,152.63,137.59,134.76,133.47,130.26,128.70,127.27,125.32,121.07,118.63,116.89,114.77,81.59,68.09,35.01,34.57,31.59,31.46,31.20,22.55,18.81.hrms(esi):c
25h24
clo
4+
[m+h]m/z计算值
+
:423.1358,实测值:423.1360.
[0213]
实施例21
[0214]
制备方法同15-1,以对氯苯酚(67μl,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物21-1(25mg,18%)及其非对映异构体21-2(33mg,23%)。
[0215][0216]
21-1:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.68(d,j=8.2hz,1h),7.27
–
7.23(m,2h),7.09
–
7.04(m,2h),6.49(t,j=3.1hz,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.4,5.9hz,1h),3.58(dp,j=9.6,6.7hz,1h),2.26
–
2.13(m,1h),2.11
–
2.02(m,1h),1.82(tt,j=14.2,3.1hz,1h),1.50
–
1.46(m,1h),1.44(s,3h),1.35(d,j=6.8hz,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ183.30,174.90,170.39,155.92,152.60,137.74,133.41,129.36(2c),128.80,127.27,125.83,125.26,118.52,118.11(2c),81.59,68.36,35.03,34.62,31.54,31.40,31.33,22.53,18.80.hrms(esi):c
25h24
clo
4+
[m+h]
+
m/z计算值:423.1358,实测值:423.1357.
[0217]
21-2:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.68(d,j=8.2hz,1h),7.25
–
7.22(m,2h),7.08
–
7.04(m,2h),6.50(t,j=3.1hz,1h),4.89(t,j=9.5hz,1h),4.38(dd,j=9.3,5.8hz,1h),3.64
–
3.54(m,1h),2.20
–
2.12(m,1h),2.12
–
2.00(m,1h),1.83(tt,j=14.2,3.1hz,1h),1.50
–
1.45(m,1h),1.44(s,3h),1.31(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.34,174.92,170.39,155.97,152.61,137.77,133.45,129.35(2c),128.76,127.28,125.80,125.28,118.62,118.06(2c),81.59,68.36,35.02,34.58,31.59,31.43,31.24,22.54,18.83.hrms(esi):c
25h24
clo
4+
[m+h]
+
:423.1358m/z计算值,实测值:423.1357.
[0218]
实施例22
[0219]
制备方法同15-1,以邻氯苯酚(57μl,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物22-1(28mg,20%)及其非对映异构体22-2(30mg,21%)。
[0220][0221]
22-1:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.68(d,j=8.2hz,1h),7.56(dd,j=8.4,1.4hz,1h),7.31
–
7.26(m,2h),6.89(td,j=7.7,1.4hz,1h),6.67(t,j=3.2hz,1h),4.87(t,j=9.5hz,1h),4.35(dd,j=9.4,5.9hz,1h),3.61
–
3.53(m,1h),2.29
–
2.20(m,1h),2.15
–
2.06(m,1h),1.82(tt,j=14.4,3.1hz,1h),1.45(s,3h),1.48
–
1.43(m,1h),1.34(d,j=6.8hz,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ183.45,174.91,170.44,152.96,152.82,137.55,133.44,130.14,128.86,127.93,127.16,125.28,123.86,121.57,118.46,116.49,81.56,69.09,35.06,34.60,31.72,31.54,31.38,22.94,18.78.hrms(esi):c
25h24
clo
4+
[m+h]
+
m/z计算值:423.1358,实测值:423.1355.
[0222]
22-2:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.68(d,j=8.2hz,1h),7.58(dd,j=8.5,1.4hz,1h),7.31
–
7.25(m,2h),6.88(td,j=7.7,1.4hz,1h),6.68(t,j=3.1hz,1h),4.88(t,j=9.5hz,1h),4.37(dd,j=9.4,5.8hz,1h),3.63
–
3.55(m,1h),2.29
–
2.19(m,1h),2.18
–
2.06(m,1h),1.82(tt,j=14.4,3.1hz,1h),1.48
–
1.43(m,1h),1.45(s,3h),1.31(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.44,174.89,170.44,152.95,152.87,137.59,133.47,130.12,128.82,127.94,127.19,125.29,123.86,121.58,118.57,116.50,81.56,69.07,35.07,34.57,31.78,31.53,31.29,22.90,18.84.hrms(esi):c
25h24
clo
4+
[m+h]
+
m/z计算值:423.1358,实测值:423.1355.
[0223]
实施例23
[0224]
制备方法同15-1,以间氟苯酚(52μl,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物23-1(30mg,22%)及其非对映异构体23-2(36mg,26%)。
[0225][0226]
23-1:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.3hz,1h),7.68(d,j=8.2hz,1h),7.22(td,j=8.3,6.9hz,1h),6.88(dd,j=8.2,2.4hz,1h),6.84(dt,j=11.0,2.4hz,1h),6.65(td,j=8.3,2.4hz,1h),6.52
–
6.50(m,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.3,5.9hz,1h),3.58(dp,j=9.6,6.6hz,1h),2.22(ddt,j=14.6,4.3,2.9hz,1h),2.06(td,j=13.7,2.9hz,1h),1.84(tt,j=14.3,3.1hz,1h),1.50
–
1.45(m,1h),1.44(s,3h),1.34(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.21,174.84,170.35,163.73(d,j=244.3hz),158.72(d,j=11.3hz),152.61,137.59,133.41,130.14(d,j=9.7hz),128.78,127.27,125.28,118.54,112.29(d,j=2.8hz),107.73(d,j=21.1hz),104.15(d,j=24.1hz),81.58,68.16,35.01,34.62,31.54,31.46,31.31,22.58,18.81.hrms(esi):c25h24
fo
4+
[m+h]
+
m/z计算值:407.1653,实测值:407.1654.
[0227]
23-2:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.68(d,j=8.2hz,1h),7.22(td,j=8.3,6.9hz,1h),6.88(dd,j=8.3,2.4hz,1h),6.83(dt,j=11.0,2.4hz,1h),6.67
–
6.62(m,1h),6.53
–
6.50(m,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.4,5.9hz,1h),3.63
–
3.55(m,1h),2.21(ddt,j=14.6,4.3,3.0hz,1h),2.06(td,j=13.7,2.9hz,1h),1.86(tt,j=14.3,3.1hz,1h),1.50
–
1.45(m,1h),1.44(s,3h),1.31(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.24,174.87,170.35,163.72(d,j=245.0hz),158.76(d,j=11.0hz),152.62,137.62,133.44,130.13(d,j=10.3hz),128.73,127.28,125.29,118.63,112.21(d,j=2.9hz),107.69(d,j=21.1hz),104.09(d,j=24.7hz),81.57,68.14,35.01,34.58,31.58,31.48,31.21,22.58,18.82.hrms(esi):c
25h24
fo
4+
[m+h]
+
m/z计算值:407.1653,实测值:407.1654.
[0228]
实施例24
[0229]
制备方法同15-1,以4-氟苯酚(76mg,0.674mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物24-1(31mg,23%)及其非对映异构体24-2(28mg,20%)。
[0230][0231]
24-1:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.68(d,j=8.2hz,1h),7.14
–
7.09(m,2h),7.01
–
6.95(m,2h),6.46(t,j=3.1hz,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.4,6.0hz,1h),3.58(dp,j=9.6,6.6hz,1h),2.18
–
2.03(m,2h),1.79(tt,j=13.8,3.0hz,1h),1.49
–
1.45(m,1h),1.45(s,3h),1.35(d,j=6.8hz,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ183.40,174.99,170.40,157.56(d,j=238.5hz),153.22,152.61,137.99,133.38,128.87,127.24,125.20,118.47,118.30,118.24,115.89,115.71,81.56,68.84,35.05,34.61,31.54,31.39,31.36,22.47,18.76.hrms(esi):c
25h24
fo
4+
[m+h]
+
m/z计算值:407.1653,实测值:407.1653.
[0232]
24-2:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.3hz,1h),7.68(d,j=8.2hz,1h),7.14
–
7.08(m,2h),7.01
–
6.94(m,2h),6.47(t,j=3.3hz,1h),4.89(t,j=9.5hz,1h),4.38(dd,j=9.4,5.8hz,1h),3.60(dp,j=9.3,6.7hz,1h),2.19
–
2.04(m,2h),1.81(tt,j=14.0,3.1hz,1h),1.50
–
1.46(m,1h),1.44(s,3h),1.32(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.43,175.01,170.40,157.56(d,j=238.5hz),153.22,152.62,138.04,133.39,128.85,127.25,125.19,118.59,118.25,118.18,115.88,115.70,81.56,68.82,35.05,34.58,31.58,31.40,31.27,22.46,18.83.hrms(esi):c
25h24
fo
4+
[m+h]
+
m/z计算值:407.1653,实测值:407.1654.
[0233]
实施例25
[0234]
制备方法同15-1,以对三氟甲基苯酚(70μl,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物25-1(47mg,31%)及其非对映异构体25-2(42mg,
27%)。
[0235][0236]
25-1:1h nmr(500mhz,cdcl3)δ7.78(d,j=8.3hz,1h),7.70(d,j=8.2hz,1h),7.54(d,j=8.5hz,2h),7.15(d,j=8.5hz,2h),6.58(t,j=3.1hz,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.4,5.9hz,1h),3.57(dp,j=9.5,6.7hz,1h),2.24
–
2.17(m,1h),2.10
–
2.02(m,1h),1.89(tt,j=14.3,3.1hz,1h),1.49(dt,j=13.6,3.6hz,1h),1.45(s,3h),1.34(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.22,174.69,170.55,160.00,152.66,137.37,133.55,128.70,127.31,126.92(q,j=3.8hz)(2c),125.44,124.56(q,j=271.1hz),122.74(q,j=32.3hz),118.58,116.14(2c),81.68,68.01,35.01,34.59,31.51,31.45,31.24,22.64,18.77.hrms(esi):c
26h24
f3o
4+
[m+h]
+
m/z计算值:457.1621,实测值:457.1623.
[0237]
25-2:1h nmr(500mhz,cdcl3)δ7.78(d,j=8.3hz,1h),7.70(d,j=8.2hz,1h),7.55(d,j=8.5hz,2h),7.14(d,j=8.6hz,2h),6.60(t,j=3.3hz,1h),4.89(t,j=9.5hz,1h),4.38(dd,j=9.4,5.9hz,1h),3.59(dp,j=9.6,6.6hz,1h),2.24
–
2.18(m,1h),2.10
–
2.02(m,1h),1.91(tt,j=14.3,3.1hz,1h),1.49(dt,j=13.4,3.6hz,1h),1.45(s,3h),1.31(d,j=6.8hz,3h),1.29(s,3h).
13
c nmr(126mhz,cdcl3)δ183.27,174.79,170.33,160.07,152.59,137.35,133.51,128.70,127.35,126.92(q,j=3.8hz)(2c),125.63(q,j=271.0hz),125.39,122.73(q,j=31.8hz),118.66,116.05(2c),81.59,67.97,34.99,34.58,31.56,31.48,31.15,22.67,18.77.hrms(esi):c
26h24
f3o
4+
[m+h]
+
m/z计算值:457.1621,实测值:457.1619.
[0238]
实施例26
[0239]
制备方法同15-1,以对溴苯酚(99mg,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物26-1(36mg,23%)及其非对映异构体26-2(39mg,25%)。
[0240][0241]
26-1:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.2hz,1h),7.67(d,j=8.2hz,1h),7.38
–
7.34(m,2h),7.02
–
6.98(m,2h),6.47(t,j=3.2hz,1h),4.88(t,j=9.5hz,1h),4.36(dd,j=9.4,5.9hz,1h),3.57(dp,j=9.5,6.7hz,1h),2.15(ddt,j=14.4,4.2,3.0hz,1h),2.04(td,j=13.7,2.9hz,1h),1.81(tt,j=14.2,3.1hz,1h),1.48
–
1.44(m,1h),1.43(s,3h),1.33(d,j=6.8hz,3h),1.26(s,3h).
13
c nmr(126mhz,cdcl3)δ183.27,174.81,170.50,156.45,152.64,137.74,133.46,132.30(2c),128.76,127.26,125.31,118.58(2c),
118.53,113.16,81.64,68.26,35.03,34.61,31.55,31.40,31.32,22.52,18.79.hrms(esi):c
25h24
bro
4+
[m+h]
+
m/z计算值:467.0852,实测值:467.0850.
[0242]
26-2:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.68(d,j=8.2hz,1h),7.40
–
7.36(m,2h),7.04
–
6.99(m,2h),6.50(t,j=3.1hz,1h),4.89(t,j=9.5hz,1h),4.38(dd,j=9.4,5.9hz,1h),3.60(dp,j=9.5,6.7hz,1h),2.20
–
2.14(m,1h),2.05(td,j=13.7,2.9hz,1h),1.84(tt,j=14.2,3.1hz,1h),1.50
–
1.45(m,1h),1.44(s,3h),1.32(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.31,174.87,170.41,156.51,152.62,137.75,133.46,132.30(2c),128.74,127.29,125.29,118.62,118.53(2c),113.15,81.60,68.25,35.02,34.58,31.59,31.42,31.24,22.54,18.82.hrms(esi):c
25h24
bro
4+
[m+h]
+
m/z计算值:467.0852,实测值:467.0852.
[0243]
实施例27
[0244]
制备方法同15-1,以间甲氧基苯酚(72μl,0.674mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物27-1(35mg,25%)及其非对映异构体27-2(34mg,24%)。
[0245][0246]
27-1:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.2hz,1h),7.67(d,j=8.1hz,1h),7.20(t,j=8.1hz,1h),6.76(dd,j=8.0,2.1hz,1h),6.65(t,j=2.2hz,1h),6.58
–
6.49(m,2h),4.88(t,j=9.4hz,1h),4.36(dd,j=9.3,5.7hz,1h),3.78(s,3h),3.62
–
3.54(m,1h),2.29
–
2.20(m,1h),2.13
–
2.02(m,1h),1.82(t,j=14.1hz,1h),1.48
–
1.45(m,1h),1.44(s,3h),1.34(d,j=7.0hz,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ183.25,175.03,170.43,160.82,158.49,152.68,138.07,133.31,129.86,128.92,127.20,125.14,118.48,108.94,106.65,103.07,81.58,67.85,55.29,35.03,34.62,31.90,31.55,31.38,22.62,18.81.hrms(esi):c
26h27o5+
[m+h]
+
m/z计算值:419.1853,实测值:419.1849.
[0247]
27-2:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.2hz,1h),7.67(d,j=8.2hz,1h),7.19(t,j=8.2hz,1h),6.76(dd,j=8.1,2.3hz,1h),6.64(t,j=2.3hz,1h),6.57
–
6.49(m,2h),4.88(t,j=9.4hz,1h),4.37(dd,j=9.4,5.6hz,1h),3.78(s,3h),3.63
–
3.56(m,1h),2.29
–
2.21(m,1h),2.12
–
2.03(m,1h),1.84(tt,j=14.2,2.9hz,1h),1.49
–
1.45(m,1h),1.44(s,3h),1.31(d,j=6.7hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.25,175.03,170.38,160.82,158.52,152.68,138.11,133.32,129.86,128.88,127.21,125.13,118.58,108.84,106.59,103.04,81.56,67.79,55.19,35.03,34.58,31.59,31.57,31.27,22.59,18.84.hrms(esi):c
26h27o5+
[m+h]
+
m/z计算值:419.1853,实测值:419.1855.
[0248]
实施例28
[0249]
制备方法同15-1,以对甲氧基苯酚(71mg,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物28-1(29mg,21%)及其非对映异构体28-2(35mg,25%)。
[0250][0251]
28-1:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.0hz,1h),7.67(d,j=8.2hz,1h),7.14
–
7.10(m,2h),6.87
–
6.80(m,2h),6.43(t,j=3.5hz,1h),4.90(t,j=9.4hz,1h),4.37(dd,j=8.9,6.3hz,1h),3.77(s,3h),3.63
–
3.54(m,1h),2.18
–
2.07(m,2h),1.80
–
1.72(m,1h),1.49
–
1.40(m,4h),1.34(d,j=6.7hz,3h),1.26(s,3h).
13
c nmr(126mhz,cdcl3)δ183.38,174.87,171.08,154.21,152.87,151.02,138.61,133.48,128.81,127.12,125.21,118.48(2c),118.40,114.64(2c),81.76,68.85,55.71,35.11,34.55,31.57,31.42,31.36,22.42,18.72.hrms(esi):c
26h27o5+
[m+h]
+
m/z计算值:419.1853,实测值:419.1853.
[0252]
28-2:1h nmr(500mhz,cdcl3)δ7.74(d,j=8.2hz,1h),7.66(d,j=8.2hz,1h),7.15
–
7.10(m,2h),6.86
–
6.80(m,2h),6.47
–
6.43(m,1h),4.87(t,j=9.5hz,1h),4.36(dd,j=8.6,6.0hz,1h),3.77(s,3h),3.63
–
3.54(m,1h),2.18
–
2.07(m,2h),1.82
–
1.73(m,1h),1.48
–
1.44(m,1h),1.44(s,3h),1.31(d,j=6.7hz,3h),1.26(s,3h).
13
c nmr(126mhz,cdcl3)δ183.48,175.09,170.43,154.26,152.67,151.08,138.44,133.32,128.96,127.17,125.07,118.53,118.49(2c),114.64(2c),81.54,68.88,55.71,35.08,34.56,31.61,31.41,31.34,22.46,18.88.hrms(esi):c
26h27o5+
[m+h]
+
m/z计算值:419.1853,实测值:419.1855.
[0253]
实施例29
[0254]
制备方法同15-1,以2-甲氧基苯酚(74μl,0.674mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物29-1(58mg,41%)。
[0255][0256]
29-1:1h nmr(500mhz,cdcl3)δ7.71(dd,j=8.2,3.8hz,1h),7.62(dd,j=8.2,1.9hz,1h),7.44(td,j=7.4,2.1hz,1h),6.97
–
6.89(m,2h),6.86
–
6.80(m,1h),6.54(t,j=3.5hz,1h),4.86(q,j=9.5hz,1h),4.34(td,j=9.2,5.9hz,1h),3.73(d,j=1.7hz,3h),3.61
–
3.51(m,1h),2.31
–
2.09(m,3h),1.92
–
1.78(m,1h),1.43(d,j=3.5hz,3h),1.31(dd,j=13.5,6.7hz,3h),1.26(d,j=3.5hz,3h).
13
c nmr(126mhz,cdcl3)δ183.76,175.29,170.48,152.84,150.47,146.86,138.40,133.00,129.63,126.95,124.92,121.64,121.08,118.23,116.99,112.05,81.49,69.59,55.79,35.06,34.53,31.76,31.44,31.40,23.15,18.81.hrms(esi):c
26h27o5+
[m+h]
+
m/z计算值:419.1853,实测值:419.1852.
[0257]
实施例30
[0258]
制备方法同15-1,以对三氟甲氧基苯酚(74μl,0.574mmol)为原料,硅胶柱层析
(pe:etoac=3:1-1:1),得桔黄色固体化合物30-1(38mg,24%)及其非对映异构体30-2(36mg,23%)。
[0259][0260]
30-1:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.69(d,j=8.2hz,1h),7.17
–
7.13(m,2h),7.13
–
7.09(m,2h),6.51(t,j=3.1hz,1h),4.88(t,j=9.5hz,1h),4.36(dd,j=9.4,5.9hz,1h),3.58(dp,j=9.6,6.7hz,1h),2.21
–
2.15(m,1h),2.10
–
2.03(m,1h),1.83(tt,j=14.3,3.1hz,1h),1.50
–
1.46(m,1h),1.44(s,3h),1.34(d,j=6.8hz,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ183.30,174.84,170.40,155.79,152.61,142.85,137.65,133.45,128.77,127.29,125.30,122.40(2c),120.59(q,j=255.8hz),118.53,117.42(2c),81.59,68.35,35.02,34.60,31.52,31.42,31.29,22.50,18.79.hrms(esi):c
26h24
f3o
5+
[m+h]
+
m/z计算值:473.1570,实测值:473.1569.
[0261]
30-2:1h nmr(500mhz,cdcl3)δ7.77(d,j=8.2hz,1h),7.69(d,j=8.2hz,1h),7.16
–
7.12(m,2h),7.12
–
7.09(m,2h),6.52(t,j=3.3hz,1h),4.89(t,j=9.5hz,1h),4.38(dd,j=9.4,5.9hz,1h),3.59(dp,j=9.7,6.7hz,1h),2.21
–
2.16(m,1h),2.10
–
2.02(m,1h),1.85(tt,j=14.3,3.2hz,1h),1.48(dt,j=13.8,3.8hz,1h),1.44(s,3h),1.31(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.32,174.87,170.44,155.83,152.63,142.82,137.71,133.48,128.73,127.30,125.31,122.40(2c),120.59(q,j=255.7hz),118.63,117.31(2c),81.60,68.29,35.02,34.57,31.56,31.44,31.19,22.50,18.79.hrms(esi):c
26h24
f3o
5+
[m+h]
+
m/z计算值:473.1570,实测值:473.1569.
[0262]
实施例31
[0263]
制备方法同15-1,以对甲基苯酚(60μl,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物31-1(33mg,24%)及其非对映异构体31-2(29mg,21%)。
[0264][0265]
31-1:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.2hz,1h),7.66(d,j=8.2hz,1h),7.12
–
7.08(m,2h),7.08
–
7.04(m,2h),6.52(t,j=3.2hz,1h),4.88(t,j=9.5hz,1h),4.36(dd,j=9.4,5.9hz,1h),3.58(dp,j=9.7,6.7hz,1h),2.30(s,3h),2.23
–
2.17(m,1h),2.15
–
2.06(m,1h),1.79(tt,j=14.1,3.1hz,1h),1.44(s,3h),1.44
–
1.41(m,1h),1.34(d,j=6.8hz,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ183.32,175.08,170.41,155.00,152.68,138.37,133.29,130.36,129.93(2c),128.94,127.19,125.07,118.42,116.91(2c),81.53,68.00,35.06,34.61,31.58,31.44,31.42,22.51,20.56,18.80.hrms(esi):c26h27o4+
[m+h]
+
m/z计算值:403.1904,实测值:403.1901.
[0266]
31-2:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.2hz,1h),7.66(d,j=8.2hz,1h),7.12
–
7.07(m,2h),7.07
–
7.03(m,2h),6.53(t,j=3.2hz,1h),4.88(t,j=9.5hz,1h),4.37(dd,j=9.4,5.8hz,1h),3.59(dp,j=9.5,6.6hz,1h),2.29(s,3h),2.22
–
2.16(m,1h),2.14
–
2.03(m,1h),1.81(tt,j=14.2,3.1hz,1h),1.47
–
1.45(m,1h),1.44(s,3h),1.31(d,j=6.8hz,3h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.36,175.08,170.39,155.03,152.68,138.40,133.30,130.36,129.92(2c),128.93,127.18,125.06,118.55,116.88(2c),81.52,68.00,35.06,34.57,31.62,31.46,31.33,22.52,20.56,18.88.hrms(esi):c
26h27o4+
[m+h]
+
m/z计算值:403.1904,实测值:403.1905.
[0267]
实施例32
[0268]
制备方法同15-1,以对乙基苯酚(70mg,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物32-1(32mg,23%)及其非对映异构体32-2(27mg,19%)。
[0269][0270]
32-1:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.2hz,1h),7.66(d,j=8.2hz,1h),7.15
–
7.10(m,2h),7.09
–
7.05(m,2h),6.53(t,j=3.2hz,1h),4.88(t,j=9.5hz,1h),4.36(dd,j=9.4,5.9hz,1h),3.58(dp,j=9.6,6.7hz,1h),2.60(q,j=7.6hz,2h),2.25
–
2.18(m,1h),2.15
–
2.06(m,1h),1.80(tt,j=14.2,3.1hz,1h),1.44(s,3h),1.48
–
1.41(m,1h),1.34(d,j=6.7hz,3h),1.27(s,3h),1.22(t,j=7.6hz,3h).
13
c nmr(126mhz,cdcl3)δ183.30,175.04,170.45,155.16,152.70,138.39,136.77,133.30,128.93,128.73(2c),127.18,125.07,118.42,116.77(2c),81.54,67.85,35.06,34.60,31.57,31.47,31.41,28.04,22.52,18.79,15.82.hrms(esi):c
27h29o4+
[m+h]
+
m/z计算值:417.2060,实测值:417.2065.
[0271]
32-2:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.2hz,1h),7.66(d,j=8.2hz,1h),7.14
–
7.10(m,2h),7.08
–
7.04(m,2h),6.54(t,j=3.1hz,1h),4.88(t,j=9.5hz,1h),4.37(dd,j=9.3,5.8hz,1h),3.63
–
3.55(m,1h),2.59(q,j=7.6hz,2h),2.25
–
2.19(m,1h),2.14
–
2.05(m,1h),1.82(tt,j=14.2,3.1hz,1h),1.48
–
1.44(m,1h),1.44(s,3h),1.31(d,j=6.8hz,3h),1.28(s,3h),1.22(t,j=7.6hz,3h).
13
c nmr(126mhz,cdcl3)δ183.33,175.07,170.38,155.21,152.68,138.43,136.77,133.29,128.93,128.72(2c),127.19,125.05,118.55,116.67(2c),81.52,67.81,35.05,34.57,31.61,31.50,31.31,28.04,22.53,18.87,15.84.hrms(esi):c
27h29o4+
[m+h]
+
:417.2060,实测值:417.2062.
[0272]
实施例33
[0273]
制备方法同15-1,以对叔丁基苯酚(86mg,0.574mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物33-1(31mg,21%)及其非对映异构体33-2(30mg,20%)。
[0274][0275]
33-1:1h nmr(500mhz,cdcl3)δ7.75(d,j=8.2hz,1h),7.67(d,j=8.2hz,1h),7.32
–
7.29(m,2h),7.07
–
7.03(m,2h),6.53(t,j=3.3hz,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.4,5.9hz,1h),3.62
–
3.54(m,1h),2.30
–
2.21(m,1h),2.14
–
2.04(m,1h),1.81(tt,j=14.3,3.1hz,1h),1.48
–
1.43(m,1h),1.44(s,3h),1.34(d,j=6.8hz,3h),1.31(s,9h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ183.27,174.90,170.75,154.88,152.84,143.47,138.55,133.40,128.88,127.16,126.25(2c),125.13,118.41,116.01(2c),81.65,67.53,35.07,34.58,34.07,31.58(3c),31.55,31.53,31.39,22.55,18.78.hrms(esi):c
29h33o4+
[m+h]
+
m/z计算值:445.2373,实测值:445.2376.
[0276]
33-2:1h nmr(500mhz,cdcl3)δ7.76(d,j=8.2hz,1h),7.67(d,j=8.2hz,1h),7.32
–
7.28(m,2h),7.06
–
7.02(m,2h),6.55(t,j=2.8hz,1h),4.89(t,j=9.5hz,1h),4.38(dd,j=9.4,5.8hz,1h),3.59(dp,j=9.5,6.6hz,1h),2.30
–
2.22(m,1h),2.13
–
2.03(m,1h),1.84(tt,j=14.2,3.1hz,1h),1.48
–
1.45(m,1h),1.44(s,3h),1.31(s,12h),1.28(s,3h).
13
c nmr(126mhz,cdcl3)δ183.28,174.93,170.70,154.95,152.81,143.42,138.58,133.38,128.86,127.18,126.23(2c),125.12,118.54,115.82(2c),81.63,67.43,35.06,34.54,34.06,31.59,31.57(3c),31.56,31.28,22.55,18.84.hrms(esi):c
29h33o4+
[m+h]
+
m/z计算值:445.2373,实测值:445.2373.
[0277]
实施例34
[0278]
制备方法同15-1,以3-氟-4-硝基苯酚(106mg,0.674mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物35-1(40mg,26%)及其非对映异构体35-2(43mg,28%)。
[0279][0280]
35-1:1h nmr(500mhz,cdcl3)δ8.08(t,j=8.9hz,1h),7.81(d,j=8.3hz,1h),7.73(d,j=8.3hz,1h),6.92
–
6.83(m,2h),6.53(t,j=3.3hz,1h),4.91(t,j=9.5hz,1h),4.39(dd,j=9.4,5.9hz,1h),3.59(dq,j=9.6,6.7hz,1h),2.23
–
2.16(m,1h),2.06
–
1.92(m,2h),1.59
–
1.52(m,1h),1.45(s,3h),1.34(d,j=6.8hz,3h),1.30(s,3h).
13
c nmr(126mhz,cdcl3)δ183.24,174.47,170.32,163.74(d,j=11.3hz),157.71(d,j=264.4hz),152.50,136.00,133.69,130.55(d,j=6.2hz),128.58,127.93,127.47,125.79,118.76,111.85(d,j=3.0hz),104.82(d,j=24.0hz),81.72,69.51,34.94,34.61,31.44(2c),31.09,22.98,
18.77.hrms(esi):c
25h23
fno
6+
[m+h]
+
m/z计算值:452.1504,实测值:452.1509.
[0281]
35-2:1h nmr(500mhz,cdcl3)δ8.08(t,j=8.8hz,1h),7.81(d,j=8.3hz,1h),7.73(d,j=8.3hz,1h),6.92
–
6.83(m,2h),6.53(t,j=2.5hz,1h),4.91(t,j=9.5hz,1h),4.39(dd,j=9.4,6.0hz,1h),3.59(dp,j=9.3,6.7hz,1h),2.22
–
2.16(m,1h),2.06
–
1.93(m,2h),1.58
–
1.53(m,1h),1.45(s,3h),1.32(d,j=6.9hz,3h),1.30(s,3h).
13
c nmr(126mhz,cdcl3)δ183.29,174.54,170.37,163.80(d,j=11.2hz),157.68(d,j=264.5hz),152.52,136.02,133.75,130.45(d,j=6.4hz),128.52,127.92,127.47,125.81,118.78,111.83(d,j=2.8hz),104.81(d,j=23.9hz),81.72,69.54,34.94,34.58,31.49,31.44,31.00,22.99,18.69.hrms(esi):c
25h23
fno
6+
[m+h]
+
m/z计算值:452.1504,实测值:452.1502.
[0282]
实施例35
[0283]
取4-(1-哌嗪基)苯酚(500mg,2.809mmol)溶于30ml四氢呋喃中,依次加入二碳酸二叔丁酯(773μl,3.370mmol),三乙胺(584μl,4.214mmol),常温下搅拌反应,tlc确认反应结束后,减压浓缩,硅胶柱层析(dcm:meoh=100:1-20:1)得粗产物a(203mg,26%)。将粗产物a(203mg,0.730mmol)溶于5ml氯苯中,依次加入隐丹参酮(127mg,0.430mmol),tempo(134mg,0.860mmol),120℃下回流反应24h,tlc确认反应完全后,减压浓缩,硅胶柱层析(pe:etoac=3:1-1:1)分离纯化,得黑褐色固体化合物36-1(42mg,17%)。
[0284][0285]
36-1:1h nmr(500mhz,cdcl3)δ7.74(d,j=8.2hz,1h),7.66(d,j=8.2hz,1h),7.13
–
7.06(m,2h),6.94
–
6.88(m,2h),6.46(dt,j=6.2,3.2hz,1h),4.88(td,j=9.5,2.8hz,1h),4.36(ddd,j=9.3,5.9,4.3hz,1h),3.62
–
3.53(m,5h),3.07
–
2.98(m,4h),2.20
–
2.03(m,2h),1.78(tdt,j=13.4,10.1,3.0hz,1h),1.48(s,9h),1.47
–
1.39(m,1h),1.43(d,j=1.9hz,3h),1.32(dd,j=16.1,6.8hz,3h),1.26(d,j=3.3hz,3h).
13
c nmr(126mhz,cdcl3)δ183.43,175.10,170.38,154.77,152.65,138.38,138.35,133.27,128.97,127.17,125.04,118.81(2c),118.52,118.40,117.95(2c),81.51,79.78,68.42,50.89(2c),35.05(2c),34.61,34.56,31.57,31.45,31.36,28.42(3c),22.53,18.81.hrms(esi):c
34h41
n2o
6+
[m+h]
+
m/z计算值:573.2959,实测值:573.2960.
[0286]
实施例36
[0287]
制备方法同1-1,以boc-甘氨酸(118mg,0.675mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物37-1(71mg,45%)及其非对映异构体37-2(78mg,49%)。
[0288][0289]
37-1:1h nmr(500mhz,cdcl3)δ7.73(d,j=8.3hz,1h),7.67(d,j=8.2hz,1h),6.48(t,j=3.6hz,1h),5.14(s,1h),4.89(t,j=9.5hz,1h),4.37(dd,j=9.9,5.5hz,1h),3.97(dd,j=18.2,7.1hz,1h),3.68(dd,j=18.2,3.9hz,1h),3.62
–
3.56(m,1h),2.25
–
2.19(m,1h),2.01
–
1.85(m,2h),1.57
–
1.51(m,1h),1.42(s,9h),1.39(s,3h),1.34(d,j=7.1hz,3h),1.26(s,3h).
13
c nmr(126mhz,cdcl3)δ183.43,174.82,170.28,169.36,155.75,152.88,136.56,133.43,129.03,127.21,125.38,118.68,81.64,79.66,68.23,42.24,34.90,34.61,32.00,31.48,31.11,28.30(3c),24.60,18.82.hrms(esi):c
26h31
no7na
+
[m+na]
+
m/z计算值:492.1993,实测值:492.1993.
[0290]
37-2:1h nmr(500mhz,cdcl3)δ7.73(d,j=8.2hz,1h),7.66(d,j=8.2hz,1h),6.47(t,j=3.5hz,1h),5.14(s,1h),4.90(t,j=9.5hz,1h),4.37(dd,j=9.4,6.1hz,1h),3.97(dd,j=18.2,7.1hz,1h),3.69(dd,j=18.2,3.9hz,1h),3.59(dp,j=9.6,6.6hz,1h),2.25
–
2.19(m,1h),2.04
–
1.84(m,2h),1.58
–
1.51(m,1h),1.42(s,9h),1.38(s,3h),1.34(d,j=6.8hz,3h),1.26(s,3h).
13
c nmr(126mhz,cdcl3)δ183.44,174.88,170.33,169.37,155.74,152.89,136.56,133.47,128.94,127.22,125.40,118.68,81.65,79.67,68.20,42.23,34.90,34.61,31.99,31.55,31.03,28.30(3c),24.61,18.67.hrms(esi):c
26h31
no7na
+
[m+na]
+
m/z计算值:492.1993,实测值:492.1995.
[0291]
实施例37
[0292]
制备方法同1-1,以boc-β-丙氨酸(128mg,0.675mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物38-1(65mg,40%)及其非对映异构体38-2(68mg,42%)。
[0293][0294]
38-1:1h nmr(500mhz,cdcl3)δ7.72(d,j=8.1hz,1h),7.66(d,j=8.2hz,1h),6.45(t,j=3.4hz,1h),5.21(s,1h),4.88(t,j=9.5hz,1h),4.37(dd,j=9.4,5.9hz,1h),3.57(dp,j=9.6,6.6hz,1h),3.42
–
3.29(m,2h),2.47
–
2.40(m,2h),2.23
–
2.15(m,1h),2.00
–
1.83(m,2h),1.57
–
1.50(m,1h),1.39(s,12h),1.33(d,j=6.8hz,3h),1.25(s,3h).
13
c nmr(126mhz,cdcl3)δ183.52,174.94,171.28,170.25,155.94,152.80,136.95,133.38,129.03,127.20,125.26,118.61,81.60,79.08,67.45,36.42,34.90,34.62(2c),32.07,31.50,31.17,28.33(3c),24.57,18.79.hrms(esi):c
27h33
no7na
+
[m+na]
+
m/z计算值:506.2149,实测值:506.2148.
[0295]
38-2:1h nmr(500mhz,cdcl3)δ7.73(d,j=8.0hz,1h),7.66(d,j=8.2hz,1h),6.44
(t,j=3.7hz,1h),5.23(s,1h),4.90(t,j=9.5hz,1h),4.37(dd,j=9.3,6.2hz,1h),3.60(dp,j=9.7,6.7hz,1h),3.45
–
3.32(m,2h),2.46(tq,j=10.0,5.2,4.5hz,2h),2.25
–
2.15(m,1h),2.03
–
1.83(m,2h),1.55(dd,j=11.6,4.7hz,1h),1.41(s,9h),1.39(s,3h),1.35(d,j=6.8hz,3h),1.27(s,3h).
13
c nmr(126mhz,cdcl3)δ183.48,175.04,171.34,170.31,155.96,152.83,136.94,133.43,129.02,127.21,125.29,118.61,81.60,79.11,67.41,36.37,34.92,34.63,34.58,32.05,31.60,31.11,28.35(3c),24.59,18.66.hrms(esi):c
27h33
no7na
+
[m+na]
+
m/z计算值:506.2149,实测值:506.2145.
[0296]
实施例38
[0297]
制备方法同1-1,以boc-l-脯氨酸(220mg,1.020mmol)、隐丹参酮(150mg,0.510mmol)、tempo(96mg,0.612mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物39-1(42mg,16%)及其非对映异构体39-2(35mg,13%)。
[0298][0299]
39-1:1h nmr(500mhz,cdcl3)δ7.70(d,j=8.2hz,1h),7.63(d,j=8.2hz,1h),6.48(t,j=3.5hz,1h),4.86(t,j=9.5hz,1h),4.33(dd,j=9.4,6.1hz,1h),4.12(dd,j=8.2,3.5hz,1h),4.05(dd,j=8.4,3.6hz,1h),3.57
–
3.48(m,1h),3.39
–
3.23(m,1h),2.21
–
2.13(m,2h),2.10
–
1.81(m,3h),1.80
–
1.71(m,1h),1.51
–
1.45(m,2h),1.38(s,3h),1.35(s,9h),1.29(d,j=6.8hz,3h),1.21(s,3h).
13
c nmr(126mhz,cdcl3)δ183.46,175.03,171.36,170.28,153.99,152.82,136.73,133.35,129.06,127.11,125.28,118.54,81.58,79.90,67.48,59.84,46.18,34.88,34.61,32.39,31.56,31.09,29.92,28.36(3c),24.41,23.43,18.60.hrms(esi):c
29h35
no7na
+
[m+na]
+
m/z计算值:532.2306,实测值:532.2304.
[0300]
39-2:1h nmr(500mhz,cdcl3)δ7.69(d,j=8.2hz,1h),7.63(d,j=8.2hz,1h),6.49(t,j=3.4hz,1h),4.88(t,j=9.5hz,1h),4.37
–
4.28(m,1h),4.25(dd,j=7.6,4.8hz,1h),3.57(dq,j=6.5,3.2hz,1h),3.35
–
3.28(m,1h),3.25
–
3.14(m,1h),2.20
–
2.09(m,3h),2.01
–
1.80(m,2h),1.75
–
1.59(m,2h),1.54
–
1.42(m,1h),1.40(s,9h),1.36(s,3h),1.34(d,j=9.6hz,3h),1.32(s,3h).
13
c nmr(126mhz,cdcl3)δ183.46,175.03,171.36,170.28,153.99,152.82,136.73,133.35,129.06,127.11,125.28,118.54,81.58,79.90,67.48,59.84,46.18,34.88,34.61,32.39,31.56,31.09,29.92,28.36(3c),24.41,23.43,18.60.hrms(esi):c
29h35
no7na
+
[m+na]
+
m/z计算值:532.2306,实测值:532.2305.
[0301]
实施例39
[0302]
制备方法同1-1,以boc-l-色氨酸(317mg,1.020mmol)、隐丹参酮(150mg,0.510mmol)、tempo(96mg,0.612mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物40-1(37mg,12%)及其非对映异构体40-2(46mg,15%)。
[0303][0304]
40-1:1h nmr(500mhz,cdcl3)δ8.68
–
8.59(m,1h),7.71(d,j=8.2hz,1h),7.63(d,j=8.2hz,1h),7.40(d,j=8.0hz,1h),7.30(d,j=8.1hz,1h),7.21(d,j=2.4hz,1h),7.06(t,j=7.6hz,1h),6.94(t,j=7.5hz,1h),6.72(d,j=3.5hz,1h),5.35(t,j=9.2hz,1h),4.89(t,j=9.5hz,1h),4.66
–
4.58(m,1h),4.35(dd,j=9.4,5.8hz,1h),3.56(dt,j=9.5,6.3hz,1h),3.19(dd,j=15.1,5.7hz,1h),3.05(dd,j=15.1,6.4hz,1h),2.24
–
2.15(m,1h),2.02
–
1.85(m,2h),1.53
–
1.43(m,1h),1.40(s,3h),1.38
–
1.31(m,12h),1.23(s,3h).
13
c nmr(126mhz,cdcl3)δ182.76,174.75,171.07,170.38,155.46,152.94,136.47,135.94,133.33,128.61,128.01,127.04,125.26,123.87,121.30,118.94,118.62,118.56,111.17,109.94,81.61,79.41,67.51,54.10,34.89,34.63,31.81,31.56,31.30,28.28(3c),27.69,24.43,18.80.hrms(esi):c
35h38
n2o7na
+
[m+na]
+
m/z计算值:621.2571,实测值:621.2571.
[0305]
40-2:1h nmr(500mhz,cdcl3)δ8.55
–
8.49(m,1h),7.66(d,j=8.2hz,1h),7.62(d,j=8.2hz,1h),7.56(d,j=7.9hz,1h),7.30(d,j=8.1hz,1h),7.15
–
7.09(m,2h),7.07
–
7.00(m,1h),6.68(t,j=3.3hz,1h),5.12(d,j=7.9hz,1h),4.89(t,j=9.5hz,1h),4.67
–
4.58(m,1h),4.36(dd,j=9.4,6.1hz,1h),3.60(dt,j=9.3,6.5hz,1h),3.33(dd,j=14.7,6.2hz,1h),3.24(dd,j=14.7,5.1hz,1h),2.07
–
2.01(m,1h),1.86
–
1.74(m,1h),1.59
–
1.39(m,2h),1.37(d,j=8.5hz,12h),1.24(s,3h),1.19(s,3h).
13
c nmr(126mhz,cdcl3)δ182.95,175.08,170.89,170.58,155.17,153.04,136.37,136.04,133.38,128.69,128.01,127.02,125.39,123.81,121.67,119.20,118.79,118.64,111.12,110.10,81.64,79.46,67.47,55.00,34.78,34.60,31.62,31.49,31.05,28.33(3c),28.03,24.33,18.71.hrms(esi):c
35h38
n2o7na
+
[m+na]
+
m/z计算值:621.2571,实测值:621.2572.
[0306]
实施例40
[0307]
制备方法同1-1,以boc-l-苯丙氨酸(275mg,1.020mmol)、隐丹参酮(150mg,0.510mmol)、tempo(96mg,0.612mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物41-1(96mg,34%)。
[0308][0309]
41-1:1h nmr(500mhz,cdcl3)δ7.72(dd,j=8.2,2.0hz,1h),7.66(dd,j=8.2,2.1hz,1h),7.21
–
7.05(m,5h),6.57(t,j=3.3hz,1h),5.00(d,j=8.7hz,1h),4.87(td,j=9.5,2.3hz,1h),4.46(td,j=8.9,5.5hz,1h),4.36(ddd,j=9.2,5.9,2.4hz,1h),3.56(ddt,j=13.0,9.3,6.0hz,1h),3.03
–
2.95(m,1h),2.87(dd,j=14.3,9.0hz,1h),2.22
–
2.13(m,1h),1.96
–
1.82(m,2h),1.53
–
1.42(m,1h),1.37(d,j=2.1hz,3h),1.35
–
1.20(m,
15h).
13
c nmr(126mhz,cdcl3)δ183.47,174.96,170.83,170.18,155.18,152.91,136.92,136.41,133.40,129.30(2c),128.99,128.08(2c),127.10,126.34,125.31,118.64,81.60,79.48,67.97,54.18,38.34,34.86,34.63,31.91,31.49,31.22,28.20(3c),24.44,18.80.hrms(esi):c
33h37
no7na
+
[m+na]
+
m/z计算值:582.2462,实测值:582.246
[0310]
实施例41
[0311]
制备方法同1-1,以boc-l-丙氨酸(197mg,1.020mmol)、隐丹参酮(150mg,0.510mmol)、tempo(96mg,0.612mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物42-1(68mg,28%)及其非对映异构体42-2(62mg,25%)。
[0312][0313]
42-1:1h nmr(500mhz,cdcl3)δ7.71(d,j=8.2hz,1h),7.65(d,j=8.4hz,1h),6.50(t,j=3.6hz,1h),5.20(d,j=8.2hz,1h),4.87(t,j=9.5hz,1h),4.35(dd,j=9.3,6.1hz,1h),4.18(p,j=7.4hz,1h),3.55(dp,j=9.1,6.6hz,1h),2.20
–
2.14(m,1h),2.03
–
1.84(m,2h),1.54
–
1.48(m,1h),1.40
–
1.37(m,12h),1.31(d,j=7.0hz,3h),1.23(s,6h).
13
c nmr(126mhz,cdcl3)δ183.40,174.97,172.03,170.24,155.16,152.86,136.56,133.36,129.00,127.15,125.31,118.61,81.59,79.48,67.98,49.24,34.87,34.61,31.99,31.41,31.14,28.29(3c),24.45,18.82,18.73.hrms(esi):c
27h33
no7na
+
[m+na]
+
m/z计算值:506.2149,实测值:506.2150.
[0314]
42-2:1h nmr(500mhz,cdcl3)δ7.72(d,j=8.2hz,1h),7.66(d,j=8.2hz,1h),6.50(t,j=3.1hz,1h),5.17(d,j=7.1hz,1h),4.89(t,j=9.5hz,1h),4.36(dd,j=9.4,6.2hz,1h),4.22(p,j=7.2hz,1h),3.64
–
3.53(m,1h),2.23
–
2.14(m,1h),1.97
–
1.81(m,2h),1.58
–
1.47(m,1h),1.43
–
1.32(m,18h),1.26(s,3h).
13
c nmr(126mhz,cdcl3)δ183.35,175.08,171.61,170.21,154.98,152.81,136.41,133.39,128.98,127.17,125.37,118.67,81.61,79.37,67.76,49.43,34.89,34.63,31.99,31.64,31.06,28.30(3c),24.41,18.93,18.66.hrms(esi):c
27h33
no7na
+
[m+na]
+
:506.2149,实测值:506.2147.
[0315]
实施例42
[0316]
制备方法同1-1,以boc-甘氨酰甘氨酸(157mg,0.676mmol)为原料,硅胶柱层析(pe:etoac=3:1-1:1),得桔黄色固体化合物43-1(43mg,24%)。
[0317][0318]
43-1:1h nmr(500mhz,cdcl3)δ7.73(d,j=8.3hz,1h),7.66(d,j=8.2hz,1h),7.00(d,j=43.7hz,1h),6.48(t,j=3.4hz,1h),5.47
–
5.37(m,1h),4.90(t,j=9.5hz,1h),4.37(ddd,j=9.0,6.1,2.3hz,1h),4.19(ddd,j=18.0,6.6,4.0hz,1h),3.94
–
3.83(m,2h),
3.79
–
3.73(m,1h),3.58(dq,j=9.6,6.4hz,1h),2.22
–
2.14(m,1h),2.01
–
1.85(m,2h),1.57
–
1.51(m,1h),1.45
–
1.42(m,9h),1.38(d,j=3.0hz,3h),1.29(d,j=37.2hz,3h),1.23(s,3h).
13
c nmr(126mhz,cdcl3)δ183.46,174.75,170.47,170.01,169.01,155.96,152.92,136.47,133.50,128.93,127.22,125.43,118.66,81.70,79.98,68.31,41.00,34.89,34.57,31.94,31.47,31.08,29.64,28.29(3c),24.60,18.77.hrms(esi):c
28h34
n2o8na
+
[m+na]
+
m/z计算值:549.2207,实测值:549.2209.
[0319]
效果实施例1隐丹参酮衍生物体外抗三阴性乳腺癌活性评价
[0320]
1、实验目的
[0321]
采用cck-8法检测五种结构类型衍生物的体外抗三阴性乳腺癌活性,初步探讨其构效关系,并优选出活性优异的衍生物进行后续活性测试。
[0322]
2、实验材料
[0323]
2.1、实验细胞
[0324]
4t1细胞(鼠腺癌)和mda-mb-231细胞(人腺癌)2种三阴性乳腺癌细胞系,均购自中国科学院上海生命科学研究院细胞资源中心。
[0325]
2.2、实验仪器与试剂
[0326][0327]
2.3、药物浓度
[0328]
0.3μm、1μm、3μm、10μm、30μm
[0329]
3、实验方法
[0330]
将处于对数生长期的要进行实验的三阴性乳腺癌细胞(4t1、mda-mb-231)按一定的细胞量接种于96孔培养板内,培养24h后,加入受试药物的无血清培养基的溶液,每种浓度5个复孔,细胞在37℃,5%co2条件下继续培养24h,加入10%cck-8的无血清培养基溶液继续培养4h,酶标仪下检测各孔吸光度。
[0331]
4、实验结果
[0332]
活性测试结果表明,隐丹参酮衍生物的初步构效关系为
①
a环烃基酸酯类侧链取代的衍生物,随取代侧链链长的增加,活性逐渐下降;当侧链包含不饱和官能团以及单保护的二羧酸时,衍生物活性增加;
②
a环芳基醚类侧链取代的衍生物中,苯环对位含吸电子取代基、邻位有取代基时有利于活性的增强;苯环对位大位阻取代基修饰时导致活性减弱;含两个吸电子取代基时较该取代基的单取代时的活性强;
③
a环被氧化类衍生物及邻醌被还原类衍生物中,邻醌被还原后的衍生物活性下降;含α,β-不饱和酮时有利于活性的增强;
④
a环氨基酸酯类侧链取代的衍生物中,侧链为α-氨基时的活性较β-氨基时强。
[0333]
全部化合物均经过粗筛,结果表1如下:
[0334]
表1
[0335]
[0336]
[0337][0338]
根据其在30μm及三个浓度时的变化趋势选取活性较优的化合物21个,通过cck-8法检测其ic
50
值,得到4个优选化合物,进一步在人三阴性乳腺癌细胞上检测其ic
50
值。
[0339]
表2优选化合物在4t1细胞上的ic
50
值
[0340]
编号ic
50
(μm)编号ic
50
(μm)编号ic
50
(μm)cts19.9616-14.4329-17.241-15.5617-25.9635-14.495-16.6918-211.2435-26.366-16.4119-12.8739-22.697-17.7122-15.6641-13.739-11.9522-26.2842-15.3113-14.5223-111.25
ꢀꢀ
15-210.3925-22.68
ꢀꢀ
[0341]
表3隐丹参酮及优选化合物在mda-mb-231上的ic
50
值
[0342]
编号ic
50
(μm)编号ic
50
(μm)编号ic
50
(μm)cts4.099-10.8613-10.5519-16.8239-21.62
ꢀꢀ
[0343]
效果实施例2隐丹参酮衍生物体内抗三阴性乳腺癌活性评价
[0344]
1、实验目的
[0345]
观察隐丹参酮优选衍生物9-1、13-1在小鼠体内抗三阴性乳腺癌的活性及安全性。
[0346]
2、实验材料
[0347]
2.1、实验细胞
[0348]
4t1(鼠腺癌)三阴性乳腺癌细胞系,购自中国科学院上海生命科学研究院细胞资源中心。
[0349]
2.2、实验动物
[0350]
spf级雌性balb/c小白鼠,5周龄,购自上海南方模式生物科技股份有限公司。饲养环境:spf级动物房,12h昼夜节律,温度(25
±
1)℃,湿度(50
±
10)%,正常自由进水,小鼠标准饲料喂养。
[0351]
2.3、实验仪器与试剂
[0352]
[0353][0354]
2.4、药物浓度
[0355]
名称:9-1;性状:红褐色粉末;溶剂:含5%dmso的食用植物油;给药浓度:15mg/kg/d
[0356]
名称:13-1;性状:黄色粉末;溶剂:含5%dmso的食用植物油;给药浓度:15mg/kg/d
[0357]
3、实验方法
[0358]
3.1、动物实验
[0359]
将4周龄的balb/c小鼠于动物中心安置一周并将腹部毛发脱去,同时准备足量的4t1细胞。取对数生长期的4t1细胞,pbs洗1次,胰酶消化终止后离心,pbs洗2次,收集细胞沉淀,用pbs混悬后计数。pbs稀释细胞悬液使其成1
×
107细胞数/ml,放于冰盒中带至动物房准备接种。用注射器吸取100μl混匀后的细胞悬液,原位接种于balb/c小鼠右侧第四对乳房垫上。待肿瘤体积约50mm3时,将动物随机分成9-1组、13-1组、对照组,每组7只,各组分别每天腹腔注射100μl的含5%dmso的实验用油、9-1(15mg/kg)的油溶液、13-1(15mg/kg)的油溶液。在给药过程中每天记录小鼠体重及肿瘤体积的数据,至给药21天后,剖出肿瘤及主要主要脏器,pbs中清洗并拍照记录肿瘤组织形态变化后,放置于4%多聚甲醛中,肿瘤组织进行he染色和ki67染色,各脏器组织进行he染色。
[0360]
实验分组
[0361][0362]
3.2.数据统计分析
[0363]
所有数据应用graphpad prism 8统计软件进行分析,采用双因素方差分析进行多组间差异分析,结果均用均数
±
标准差(mean
±
sd)表示;p《0.05表示具有统计学差异。
[0364]
4.实验结果
[0365]
4.1优选化合物9-1及13-1的体内药效学评价
[0366]
(1)肿瘤体积、重量及形态变化
[0367]
balb/c小鼠接种4t1细胞3天后,肿瘤可生长至50mm3左右,随机分三组后开始给药,至第25天停止给药。如说明书附图图1、2和3所示,由肿瘤体积生长曲线图a、c可以看出在给药过程中对照组、9-1组、13-1组肿瘤体积均在不断增加,对照组肿瘤生长更快,随给药周期的增加,9-1及13-1组与对照组肿瘤体积大小的差距越来越大,且差异有统计学意义;
由图3可以看出对照组的肿瘤体积最大,9-1及13-1组的肿瘤体积均较对照明显缩小,说明小鼠给药治疗后明显抑制了肿瘤体积的生长;由肿瘤重量图b、d可以看出给药21天分离出的肿瘤中,对照组最重,无治疗作用,而9-1及13-1组的肿瘤重量明显降低,且差异具有统计学意义,可见化合物9-1及13-1对肿瘤有明显的治疗作用,该结论与小鼠体积变化情况一致。
[0368]
(2)肿瘤组织的he染色及ki67免疫组织化学结果
[0369]
根据各组肿瘤组织切片的he染色结果(图4)可知,对照组坏死面积比率为20.68
±
2.30%,且细胞间排列紧密,状态饱满;9-1组坏死面积比率为59.55
±
0.38%,13-1组坏死面积比率为62.77
±
2.90%,这两组肿瘤组织坏死明显较对照组增加,且细胞间排列稀疏,细胞核大面积破裂皱缩,细胞结构消失,肿瘤组织损伤严重。后又进一步考察9-1及13-1对肿瘤细胞增殖活力的影响,通过免疫组织化学法对各组肿瘤组织切片进行ki67染色,结果表明,对照组的ki67阳性率为18.08
±
0.42%,远高于9-1组及13-1组分别为2.23
±
0.16%、3.01
±
0.27%的阳性率,差异具有统计学意义,说明两种化合物给药后均能明显降低4t1细胞在体内的增殖活力,有效的抑制肿瘤的生长。
[0370]
4.2优选化合物9-1及13-1的体内安全性评价
[0371]
(1)荷瘤小鼠的体重变化
[0372]
如图5所示,在给药期间的小鼠体重无明显变化,基本保持在一个稳定的正常水平,除对照组小鼠随肿瘤体积的增大,行动变得缓慢外,其他两组给药组无异常行为,各组小鼠均进食正常,表明腹腔注射药物并不会引起小鼠严重不良反应的发生。
[0373]
(2)各脏器组织器官的he染色
[0374]
给药25天后,取出各组小鼠的各器官进行he染色观察主要脏器的坏死情况(图6)。结果如图所示,各组的切片均未观察到异常坏死的情况,与对照组相比,无明显区别。说明给药治疗后,各器官组织形态良好,并未发现明显的毒副作用。